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ABSTRACT 
Vacuolar ATPase (V-ATPase) is responsible for maintaining the acidic pH of the 
endomembrane system in eukaryotic cells. V-ATPase active transport of protons 
generates the differential luminal pH in lysosomes, endosomes, and the Golgi. In 
addition to intracellular V-ATPase, cancer cells have V-ATPase at the plasma membrane. 
Plasmalemmal V-ATPase acidifies the extracellular milieu and enhances cell motility and 
invasion, evidence that V-ATPase contributes to tumorigenic phenotypes. We studied V-
ATPase cellular functions in prostate cancer (PCa), the most commonly diagnosed 
cancer for men in the United States. V-ATPase inhibitors decreased invasion and 
migration of PCa cells. In aggressive PCa cell lines, C4-2B and PC3, V-ATPase was 
detected in plasma membrane enriched extracts and near the leading edge of migrating 
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cells, respectively. V-ATPase was very abundant in the Golgi and clathrin-coated vesicles 
(CCV) of all the cell lines studied (LAPC4, LNCaP, C4-2B and PC3). V-ATPase inhibition 
increased the endo-lysosomal pH and altered F-actin organization and membrane 
traffic. Accrued cytosolic vesicles included CCV, recycling endosomes, and secretory 
vesicles.  Prostate Specific Antigen (PSA) accumulated in the cytosol and its secretion of 
was reduced. PSA mRNA expression was reduced as well. The androgen receptor (AR) 
that controls PSA transcription was inhibited and AR protein and mRNA reduced by 50% 
or more. Moreover, V-ATPase inhibition increased cellular levels of the subunit α of 
hypoxia inducible factor 1 (HIF-1α), a transcription factor that regulates tumorigenesis.  
V-ATPase-dependent HIF-1α accumulation repressed AR expression that was rescued by 
iron in LNCaP and LAPC4 cells. Thus, V-ATPase-dependent pH and iron homeostasis can 
be altered to target androgen-AR signaling to inhibits cell proliferation in prostate 
tumors.  
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CHAPTER I: INTRODUCTION 
1.1. Vacuolar- H+ ATPase: Structure and Function 
V-ATPase is a multi-subunit protein complex that uses the energy of ATP 
hydrolysis to transport protons across membranes. It consists of 14 different subunits 
arranged in two functional domains: V1 and Vo [1–3]. The subunits in the catalytic 
domain (V1) hydrolyze ATP at the cytosolic side of the membrane. The subunits 
embedded in the membrane, form the proton-translocating domain (Vo) that transfers 
protons from the cytosol to the lumen (Figure 1.1). In mammalian cells, some subunits 
can present one or more isoforms (Table 1.1). 
V-ATPase transports protons by a rotary mechanism [1–3] . Protons in the cytosol 
enter to a hemichannel in the subunit Voa, then protonate a glutamic acid residue in 
each subunit of the proteolipid ring (subunits c, and c” in mammalian) (Figure 1.1).  ATP 
hydrolysis in the V1 domain (at the interface between V1A and V1B subunits) drives 
rotation of the proteolipid ring (also called the c-ring). After rotation, protons are 
displaced from the Voc subunits to a second hemichannel of Voa subunit in the luminal 
side of the membrane [1,2,4]. 
V-ATPase localizes in the membrane of acidic organelles: endosomes, lysosomes, 
Golgi Apparatus, clathrin-coated vesicles and secretory vesicles [1–3,5].  Transport of 
protons across the endomembrane system by V-ATPase is responsible for the 
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acidification of intracellular compartments. It also generates the membrane potential 
that activate other transporters [2]. In all eukaryotic cells, V-ATPase organelle 
acidification contributes to several processes. These processes include: lysosome 
biogenesis and function, protein transport through the Golgi compartment, endosomal 
vesicle budding and cargo distribution, and receptor- and clathrin-mediated 
endocytosis. [4]. In some specialized cells, V-ATPase is also present in the plasma 
membrane and acidifies the extracellular environment. Some examples of cells with 
plasmalemmal V-ATPase are the clear cells of the epididymis [6,7], alpha intercalated 
cells of the kidney [8], and osteoclasts [9]. Plasma membrane -associated V-ATPase 
acidifies the extracellular matrix increasing migration and invasive phenotypes in several 
cancer cell lines [5,10,11].  
1.2. V-ATPase in Cancer 
V-ATPase is upregulated in tumors and tumor cell lines and V-ATPase function 
participates in several cellular processes that contribute in carcinogenesis (Figure 1.2). 
Hence, V-ATPase has been proposed as a new target for several types of cancer [1]. 
Highly invasive tumor cell lines express V-ATPase on the plasma membrane [5,11–14]; 
Plasmalemmal V-ATPase contributes to extracellular acidification, which promotes the 
activation of enzymes (e.g., cathepsins, matrix metalloproteinases) that degrade the 
extracellular matrix and promote tumor motility and invasion [14,15]. In addition, 
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plasmalemmal V-ATPase promotes angiogenesis [16,17] as it aids migration of 
microvascular endothelial cells.  
V-ATPase confers drug resistance to cancer. Cancer cell lines that are more 
resistant to chemotherapy express higher levels of V-ATPase subunits [18,19]. 
Essentially, V-ATPase contributes to drug resistance by two means. V-ATPase acidifies 
the extracellular milieu, which decreases the uptake of chemotherapy drugs [20–23];  
and, V-ATPase acidifies intracellular organelles is required for drug sequestration in 
acidic vesicles and lysosomes [24–26]. Thus, V-ATPase inhibition makes drug resistant 
cell lines responsive to therapy [23,27] and increases chemosensitivity in mouse 
xenograft [27].   
V-ATPase helps tumors to scape immune detection and destruction [28]. 
Expression of V-ATPase (specifically with Voa2 subunit isoform) is associated with 
macrophage polarization in tumor tissues [29]. Notably, V-ATPase inhibition decreases 
the accumulation of tumor-associated macrophages [29] and tumor-associated 
neutrophils [30] in tumor microenvironment.  
V-ATPase is crucial in autophagy and apoptosis. Therefore, is important for 
cancer cell survival. Lysosomal pH regulation by V-ATPase is essential for autophagy, 
and allows tumor cells to survive in stress conditions [31]. V-ATPase proton transport 
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also increases the cytosol pH, which limits apoptosis [32]. Thus, V-ATPase inhibitors 
promote apoptosis by both caspase dependent and independent pathways. [33–38].  
1.3. Prostate Cancer 
The prostate is a gland, part of the male reproductive system, located in the 
pelvis, just inferior to the bladder. Its function is to generate and secrete substances that 
nourishes and protects sperm [39]. Prostate Cancer (PCa) is the 1st most commonly 
diagnosed cancer and the 3rd leading cause of death for men in the United States [40]. 
PCa is any cancer that develops from tissues of the prostate. Almost all PCa develop 
from gland cells (adenocarcinomas) [41]. Rare forms of PCa include sarcomas [42], small 
cell carcinomas [43], neuroendocrine tumors [44], and transitional cell carcinomas [45]. 
Androgens are required for prostate development and normal prostate function 
[40,46,47]. However, androgens increase proliferation of PCa cells [47]. Since PCa tumors 
are initially androgen dependent [46], androgen deprivation therapy (ADT) is a common 
treatment for PCa. ADT either by surgery (i.e., orchiectomy) or chemical treatment to 
decrease serum testosterone to a minimun (i.e., < 50 ng/dl) [47,48] often results in 
regression of androgen-dependent tumors. Unfortunately, tumors frequently become 
androgen independent and typically recur with increased metastatic ability [46]. These 
Ablation Resistant Prostate Cancer (ARPC) tumors lower the relative survival rate of 
patients [41,46,47,49].  
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The main circulating androgen is testosterone. Testosterone enters prostate cells 
and PCa cells and is converted to dyhidrotestosterone (DHT) by the enzyme 5α-
reductase [46]. DHT binds to the AR and stimulates AR phosphorylation.  
Phosphorylated AR dimerizes and translocates to the nucleus where it can bind to 
androgen-response elements (ARE) in the promoter regions of AR target genes [47]. AR 
is a transcription factor member of the steroid nuclear receptor family [46,49] with more 
than 150 co-regulators that crosstalk to numerous signaling pathways (Table 1.2.) [50]. 
AR controls genes involved in proliferation, apoptosis, migration, invasion, and 
differentiation.  
In ARPC PCa cells have developed several strategies to survive and proliferate in 
low testosterone. Including overexpression of the AR, AR mutations that bind different 
ligands or can be activated without ligand [46]. Drugs that block AR expression are 
valuable tools in PCa therapy, including ARPC that is resistant to traditional therapies. 
1.4. V-ATPase in Prostate Cancer  
V-ATPase is important for PCa invasion, metastasis, and even for cell death.  For 
example, the pigment epithelium-derived factor (PEDF), an inhibitor of angiogenesis 
down-regulated in PCa cells, decreases expression of the V-ATPase subunit Voa4 isoform 
in LNCaP-CL1 cells, but not in the less invasive LNCaP cells [51]. The Voa4 subunit 
isoform also has been associated with higher metastatic potential and plasmalemmal V-
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ATPase localization in breast cancer cells [5], suggesting that a possible mechanism by 
which PEDF inhibits angiogenesis in invasive PCa cells is decreasing plasmalemmal V-
ATPase expression [51]. V-ATPase is regulated by the tumor metastasis suppressor gene 
1 (LASS2/TMSG1) that direct interacts with the V-ATPase subunit Voc. However, the 
mechanism by which LASS2/TMSG1 modulates V-ATPase is unknown [52–54]. V-ATPase 
inhibition using lejimalide B promotes cell cycle arrest in LNCaP and PC-3 cells [55]; It 
prompts apoptosis in LNCaP cells [55]. V-ATPase inhibition can block cell death in PCa 
cells (LNCaP) and other cancer cell lines treated with the α1-adrenergic antagonist 
prazosin, which induces apoptosis [56]. V-ATPase is component of PCa exosomes that 
have been shown to modify tumor microenvironment [57]. In the PCa cell line PC-3, 
exosome uptake decreases in cells treated with V-ATPase inhibitors, indicating that 
functional V-ATPase is crucial for prostasomes and exosomes uptake [58].  
In summary, V-ATPase involvement in invasion, cell proliferation, cell death, and 
exosome function has been reported in PCa cells. However, the mechanisms involved 
are not known. We hypothesize that V-ATPase dependent organelle pH regulation 
is crucial for PCa survival.  This study examines downstream consequences of 
organelle pH dysfunction after inhibiting V-ATPase in several PCa cell lines that 
represent the different stages of PCa, from androgen responsive to non-responsive and 
highly aggressive cell models. We used 4 different PCa cell lines (Table 1.3.) to study 
different roles of V-ATPase in PCa. Our work is divided in the following aims: 
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Aim 1. To explore the distribution and functions of V-ATPase in the PCa cells PC-3.   
Rationale: It has been shown in different tumors that highly invasive cell lines have V-
ATPase on the plasma membrane and that plasmalemmal V-ATPase promote motility 
and invasion [5,11–14].  However, our studies showed that most of the V-ATPase in PCa 
were distributed in vesicles around the cytosol. We use the highly invasive PCa cell line 
PC-3 (Table 1.3.) to get a deep insight about the cellular distribution of V-ATPase and 
how V-ATPase inhibition decreases motility and invasion in this cell model. These results 
are presented in Chapter IV: “F-actin reorganization by V-ATPase inhibition in prostate 
cancer.” (published: Licon et al., Biology Open 2017 6: 1734-1744). This study showed 
that treatment with the V-ATPase inhibitors bafilomycin A (BAA) and concanamycin A 
(CCA) impaired endo-lysosomal pH, vesicle trafficking, migration, and invasion in PC-3 
cells. This chapter additionally describes new V-ATPase-dependent F-actin ring 
assemblies. My contributions to this chapter were to perform all the experiments, 
complete the analysis and write the manuscript. 
Aim 2. To explore V-ATPase roles in PSA biology. Rationale: Preliminary data in our 
laboratory showed high degree of co-localization between V-ATPase and Prostate 
Specific Antigen (PSA). PSA is a serine protease commonly used as a serum marker for 
PCa [59]. Therefore, we were interested in the contributions of V-ATPase in PSA biology. 
The results obtained are presented in Chapter III: “Inhibitors of Vacuolar ATPase Proton 
Pumps Inhibit Human Prostate Cancer Cell Invasion and Prostate-Specific Antigen 
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Expression and Secretion” (published: Michel et al., 2013. International Journal of Cancer. 
2013 Jan 15; 132(2): E1–E10). This study showed that inhibition of V-ATPase decreases 
proliferation, invasion and PSA secretion in LNCaP and C4-2B cells. V-ATPase inhibition 
also decreased PSA protein and mRNA expression levels. My contribution of this project 
was making the analysis and experiments required by the reviewers (i.e., perform 
invasion assays, quantify Androgen Receptor [AR] & PSA in western blot of whole cell 
lysates, validate specificity of the V1A subunit antibody, isolate plasma membrane 
fractions, perform some immunocytochemistry experiments and generate co-
localization analysis of all immunocytochemistry data). These experiments and analysis 
contributed to the final version of Figures 1 to 6 in the published articled.  
Aim 3. To explore the mechanism by which V-ATPase inhibition decreases AR 
expression. Rationale: Since PSA transcription is controlled by AR, we studied the effect 
of V-ATPase inhibition in AR biology. Our laboratory reported that V-ATPase inhibition 
down-regulates AR protein levels in LNCaP cells (Chapter III) [11]. This finding is 
important because suppression of AR expression is a desirable mechanism to manage 
PCa. The results obtained from this aim are presented in Chapter II: “V-ATPase-
Dependent Repression of Androgen Receptor in Prostate Cancer Cells” (Licon et al., 
manuscript submitted to Oncotarget for peer-review). We showed that AR levels 
(protein and mRNA) decrease after treatment with the V-ATPase inhibitor concanamycin 
A (CCA) in LNCaP and LAPC4 cells. In this chapter, we dissected the mechanism how V-
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ATPase inhibitors blocked AR inhibition.  My contributions to this chapter were to 
develop a research hypothesis, write a proposal, perform all the experiments and 
analysis and write the manuscript.   
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Figure 1.1. V-ATPase structure 
The subunits in the catalytic domain (V1) hydrolyze ATP at the cytosolic side of the 
membrane. The subunits embedded in the membrane, form the proton-translocating 
domain (Vo) that transfers protons from the cytosol to the vesicle lumen 
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Tables 1.1. V-ATPase subunit isoforms in Yeast and Mammalian Cells    
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Figure 1.2. V-ATPase roles in cancer 
V-ATPase function is necessary for endocytosis of receptor-ligand complexes and receptor 
recycling.  It is also essential for proper transport of newly synthesized proteins through the 
exocytic pathway. V-ATPase activity contributes to several important signal transduction pathways 
(e.g., HER2, Wnt, Rac, VEGF).  V-ATPase activity is required for activation of pro-proteins including 
matrix metalloproteinases and cathepsins which degrade extracellular matrix and promote cell 
motility.  The V1 domain of V-ATPase may also directly promote cell motility by promoting 
assembly and enhancing polymerization of F-actin.  V-ATPase activity is likely also required by 
endothelial cells to increase recruitment and proliferation and is associated with activation of 
tumor-associated macrophages. 
Modified from: Fordyce C.A., Grimes M.M., Licon-Munoz Y., Chan CY., Parra K.J. (2016) Vacuolar ATPase in Physiology and 
Pathology: Roles in Neurobiology, Infectious Disease, and Cancer. In: Chakraborti S., Dhalla N. (eds) Regulation of Ca2+-
ATPases,V-ATPases and F-ATPases. Advances in Biochemistry in Health and Disease, vol 14. Springer, Cham 
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Table 1.2. Co-regulators of Androgen Receptor    
 Cellular Function Examples 
Components of the 
chromatin remodeling 
complex 
ARIP4, BRG1, hBRM, BAF57, SRG3/BAF155 
Histone Modifiers Acetyltransferases and deacetylases (SRC-1,2 and 3; p300, CBP, 
P/CAF, Tip60, HBO1, several HDACs). Methyltransferases and 
demethylases (CARM1/PRMT5, PRMT1, G9a, NSD1/ARA267α, 
LSD1) 
Ubiquitination/proteas
ome pathway 
E6-AP, Mdm2, PIRH2, SNURF/RNF4, Chip, ARNIP, USP10 
Sumoylation pathway SUMO-1, SUMO-2, SUMO-3, Ubc9, PIAS1, PIAS3, PIASxα 
Splicing and RNA 
metabolism 
PSF, PSP1, PSP2, p54nrb, p102 U5snRNP/ANT-1, hnRNPA1, 
p44/MEP50 
DNA repair  Ku70, Ku80, DNAPKc, Rad9, BRCA1, BRCA2 
Chaperones and 
cochaperones 
Hsp40, Hsp90, Hsp70, DjA1, Cdc37, FKBP52, Bag-1L 
Cytoskeletal proteins Actin, supervillain, Gelsolin, Filamin, Filamin-A, α-actinin-2, α-
actinin-4, Transgelin 
Protein involved in 
endocytosis 
HIP1, APPL, GAK, auxilin2, caveolin-1 
Signal integrators and 
transducers, scaffolds 
and adaptors 
ARA55, Paxilin, FHL2, Vinexin-α, Vav3, Rho GDI, Ack1, PRK1, 
RanBPM, ARA24/Ran, PAK6, RACK1, STAT3, Smad3, EBP1, 
Hey1, Hey2, RNase L, β-catenin, GSK-3β 
Cell cycle regulators Cyclin E, cdc25b, CDK6, Cyclin D1, Rb, pp32, RbaK 
Regulators of 
apoptosis  
Caspase 8, Par-4 
Viral oncoproteins  E2, E6, E7, Hbx  
Nuclear receptor 
coregulators 
Asc-1, Asc-2, Trap/mediator complex proteins, CoCoA, NRIP, 
PNRC, TIF1-, MRF1, PDIP1, Zac1, GT198, ARA70, Alien, AES, 
SMRT,NCoR, RIP140 
Kinases and 
phosphatases 
MAK, ANPK, Dyrk1A, ERK8, RSK, SCP2, PP2A 
Diverse functions PTEN, Tob1, Tob2, DJ-1/PARK7, DJBP, L-dopa-decarboxylase, 
SRA 
 
(Modified from: Heemers, F. and Tindall (2007). Androgen Receptor (AR) Coregulators: A Diversity of 
Functions Converging on and Regulating the AR Transcriptional Complex. Endocr. Rev. 28, 778–808.) 
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Table 1.3. Prostate Cancer Cell Lines used in our studies 
Cell Line Origin Androgen 
Receptor 
Androgen 
Sensitivity 
Tumorigenicity Chapter 
LNCaP Lymph node 
metastasis 
Mutated Sensitive Low II, III 
C4-2B Bone metastasis 
from castrated 
mice implanted 
with LNCaP 
cells 
Mutated Insensitive High III 
LAPC4 Lymph node 
metastasis 
Wild type Sensitive Low II 
PC-3 Bone metastasis Absent Insensitive High IV 
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2.1. Abstract 
 Prostate Cancer (PCa) is the most commonly diagnosed cancer and the third 
leading cause of death for men in the United States.  Suppression of androgen receptor 
(AR) expression is a desirable mechanism to manage PCa.  Our studies showed that AR 
expression was reduced in LAPC4 and LNCaP PCa cell lines treated with nanomolar 
concentrations of the V-ATPase inhibitor concanamycin A (CCA). This treatment 
decreased PSA mRNA levels, indicative of reduced AR activity. V-ATPase-dependent 
repression of AR expression was linked to defective endo-lysosomal pH regulation and 
reduced AR expression at the transcriptional level. CCA treatment increased the protein 
level and nuclear localization of the alpha subunit of the transcription factor HIF-1 (HIF-
1α) in PCa cells via decreased hydroxylation and degradation of HIF-1α. The addition of 
iron (III) citrate restored HIF-1α hydroxylation and decreased total HIF-1α levels in PCa 
cells treated with CCA. Moreover, iron treatment partially rescued CCA-mediated AR 
repression. Dimethyloxalylglycine (DMOG), which prevents HIF-1α degradation 
independently of V-ATPase, also decreased AR levels, supporting our hypothesis that 
HIF-1α serves as a downstream mediator in the V-ATPase-AR axis. We propose a new V-
ATPase-dependent mechanism to inhibit androgen receptor expression in prostate 
cancer cells involving defective endosomal trafficking of iron and the inhibition of HIF-1 
α-subunit turnover. 
2.2. Introduction 
The luminal pH of intracellular compartments is highly controlled [1–3].  A critical 
enzyme involved in the process of pH regulation is the vacuolar (H+) – ATPase (V-
ATPase). V-ATPase is a proton pump located at intracellular compartments of the 
endomembrane system (e.g., endosomes, lysosomes, Golgi-derived vesicles, clathrin-
coated vesicles, secretory vesicles) and the plasma membrane of eukaryotic cells 
specialized for active proton secretion [4,5]). V-ATPase is a multi-subunit complex that 
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has 14 different subunits arranged in two functional domains.  V1 is the catalytic domain 
on the cytosolic side of the membrane. It is composed of eight subunits 
(A3B3CDE3FG3H). The V1 domain hydrolyzes ATP and has three catalytic sites located at 
the interface of alternating subunits A and B.  The Vo domain is the proton translocation 
domain and consists of six subunits (a, c, c´´, d, e and Ac45 in mammals).  The Vo domain 
subunits c and c” form a proteolipid ring structure that rotates when protons are 
transferred across the membrane [1,2,5].   V-ATPases are frequently overexpressed in 
tumors and tumor cell lines [4,6,7], suggesting that proper control of organelle pH is 
essential for cellular health. V-ATPase has been reported to aid in tumor invasion and 
migration [4,8–12], drug resistance to chemotherapy [13–16], and cell death [17–20]. 
Prostate Cancer (PCa) is the most commonly diagnosed cancer and the third 
leading cause of death for men in the United States [21]. Normal prostate cells and early 
stage PCa cells depend upon androgen activity for growth and survival [22–24]. Thus, 
androgen ablation is a common therapy for PCa, often resulting in the regression of 
androgen-dependent tumors. However, tumors frequently become androgen-
independent and typically recur with increased metastatic ability [22–26]. These Ablation 
Resistant Prostate Cancer (ARPC) tumors lower the relative survival of patients. 
Suppression of androgen receptor (AR) expression is a desirable mechanism to manage 
PCa.  
Hypoxia inducible factor 1 (HIF-1) is a transcription factor that regulates oxygen 
homeostasis [27], angiogenesis [28,29], glucose metabolism [30], invasion [29,31] and 
cell survival [29]. Hence, its regulation is important for cancer progression [32]. HIF-1 is 
overexpressed in PCa tumors and can be regulated by androgen activity [33]. HIF-1 is a 
heterodimer with two subunits: HIF-1β, which is constitutively expressed, and HIF-1α, 
which is hydroxylated and targeted for degradation by the von Hippel-Lindau (VHL) 
ubiquitin ligase in normoxic conditions [32,34,35]. In carcinogenesis, HIF-1 has a dual 
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function: it can induce the expression of genes that promote both hypoxic adaptation 
(e.g., VEGF, GLUT-1, PGK, LDH-A[27–30]) and apoptosis (e.g., NIX, NIP3, p53 [34,36]).   
In this study, we propose a new mechanism to inhibit AR expression in prostate 
cancer cells. We show that AR expression is reduced in PCa cell lines treated with the V-
ATPase inhibitor concanamycin A (CCA). We demonstrate that this effect is a result of 
decreased HIF-1α hydroxylation and turnover that is linked to V-ATPase-dependent 
defects in the endosomal traffic of iron. This pathway can be used to modulate AR 
expression and eventually lead to the development of novel therapeutic tools for 
prostate cancer.   
2.3. Materials and methods 
Cell lines and conditions 
LAPC4 cells (kind gift from Christopher M. Heaphy, PhD) were grown in ISCOVE’s 
Modified Dulbecco’s Medium containing 10% FBS and 1 nM R1881. LNCaP cells 
(purchased from ATCC) were cultured in RPMI-1640 media supplemented with 10% fetal 
bovine serum (FBS). Cells were authenticated using short tandem repeat profiling and 
were free of mycoplasma contamination.  Cells were maintained at 37°C and 5% CO2 in 
a humidified atmosphere. Cells were exposed to vehicle (0.01% DMSO, SIGMA), 
concanamycin A (10 nM, Enzo Scientific), chloroquine (50 µM, Sigma), iron (III) citrate 
(500µM, Sigma), and/or dimethyloxalylglycine (2-5mM, Cayman Chemicals) for 24 hours 
unless otherwise indicated. Cell viability under certain treatments was assessed with 
Tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) Assays 
(ATCC) where indicated. All experiments were performed with cells less than 50 passage 
and with at least three biologically independent experiments. 
Quantitative real-time PCR (qPCR) 
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RNA was isolated using the Roche High Pure RNA isolation kit and reverse transcribed 
with the RETROscript® cDNA kit. qRT-PCR was performed with SYBR Green I Mastermix 
on a Roche LightCycler 480 II.  Analysis was performed using Δ/ΔCt method and 
expression of β-glucuronidase (GUSB) was used as an internal standard. Primer 
sequences are listed in Table 1. 
Table 1. Primers used in qRT-PCR  
Protein Forward Primer 5′- 3′ Reverse Primer, 5′- 3′ 
GUSB CTCATTTGGAATTTTGCCGATT CCGAGTGAAGATCCCCTTTTTA 
AR ATGGGACCTGAGCTGTTGGAA GTTCCAATGCAGGAAACTGCC 
PSA AGCCCCAAGCTTACCACCTG TCAGGGGTTGGCCACGATGG 
 
Western blotting 
Whole cell lysates (WCL) were prepared using RIPA buffer (25 mM Tris, 8 mM MgCl2, 1 
mM DTT, 15% glycerol, 1% Triton X-100 and protease inhibitor cocktail (SIGMA)). 
Protein concentrations were determined using bicinchoninic acid assay (BCA) assay 
(Pierce) against a BSA standard curve. For each Western sample, 50- 100 µg total protein 
of WCL were diluted in 4X Laemmli Buffer and loaded on 8% polyacrylamide gels.  
Primary antibodies against AR (Santa Cruz Biotechnology), HIF-1α (abcam), 
hydroxyproline-HIF-1α (Millipore), and β-actin (SIGMA) were diluted in 5% milk in TBS-T 
at 1:1000 concentration.  Immunoblots were imaged using the ChemiDocTM XRS 
workstation (BioRad).  Densitometry quantification of western blot bands was performed 
using ImageJ software. 
pH measurements 
Acridine orange: To qualitatively assess changes in pH of acidic vesicles, cells were 
incubated with acridine orange (SIGMA, 1 µM) for 30 minutes at 37oC, then incubated 
with 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (1 µg/ml; SIGMA) for 5 
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minutes. Cells were fixed on glass slides with 4% paraformaldehyde. Slides were imaged 
in Zeiss LSM 800 Airyscan Confocal microscope. 
Endosome/Lysosome pH measurements: To quantitatively assess pH in endo-lysosomes, 
cells were incubated with 1 mM 8-Hydroxypyrene-1,3,6-trisulfonic acid (HPTS) (Life 
Technologies) for ~16 hours, then incubated with the drug of interest for 1 hour. 
Fluorescence was measured using a FluoroMax 4 spectrofluorometer (Horiba Jobin 
Yvon) with an excitation ratio of 458/405 nm at a fixed emission of 515 nm. The HPTS 
fluorescence excitation 458/405 ratio was converted to pH values by comparison to 
standard curves generated using known pH buffers (i.e., pH 5 to pH 8) analyzed by an 
exponential growth equation.  
Immunocytochemistry  
Cells were fixed with 4% paraformaldehyde following permeabilization with 0.02% 
TritonX-100. Cells were blocked with 5% goat serum (GS). Incubation with primary 
antibodies against HIF-1α (Abcam) and Transferrin Receptor (Invitrogen) was performed 
at 1:100 dilution in 5% GS for 1 hour. Cells were washed with phosphate buffer saline 
(PBS) and incubated for 30 minutes with the secondary fluorescent antibodies (AF488 
and AF546, Invitrogen; 1:500 in 5% GS), then incubated with DAPI (1 µg/ml; SIGMA) for 5 
minutes.  Cells were washed with PBS and mounted onto microscope slides in mounting 
media. Slides were imaged in Zeiss LSM 800 Airyscan Confocal microscope. All steps 
were performed at room temperature. 
Statistical analysis 
Non-paired Student’s t-tests or Mann-Whitney tests were performed to determine 
statistically significance between control and experimental groups. Statistical analysis 
was performed using GraphPad Prism 5 software. 
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2.4. Results 
V-ATPase is required for androgen receptor expression. The prostate-specific 
antigen (PSA) is a serine protease that cleaves semenogelins in the seminal coagulum. 
PSA is the most commonly used PCa biomarker. In an earlier study, we reported that 
treatment with the V-ATPase inhibitor bafilomycin A (BAF, 10 nM) decreased mRNA 
levels of PSA in the PCa cell line LNCaP [12]. We validated those studies by showing that 
a second V-ATPase inhibitor, concanamycin A (CCA), also inhibited PSA mRNA 
expression in the LAPC4 and LNCaP PCa cell lines. We observed a significant reduction 
in PSA mRNA levels (50 - 60%) after a 24 hour treatment with 10 nM CCA (Figure 1A). 
We verified that cell survival was not compromised by this dose of CCA (Supplemental 
Figure 1).  
PSA gene expression is regulated by the transcriptional activity of the Androgen 
Receptor (AR) [37].  Thus, we next asked whether V-ATPase inhibition impaired AR 
function. We first examined AR protein expression in whole cell lysates of LAPC4 and 
LNCaP cells treated with CCA for 24 hours. Immunoblot analyses using a monoclonal 
antibody against AR showed significantly decreased AR protein levels (~90% less in 
LNCaP and ~49% less in LAPC4) in cells exposed to the V-ATPase inhibitor compared to 
untreated controls (Figure 1B).  
We measured AR mRNA to determine whether the reduction in AR protein was 
associated with reduction in AR mRNA expression. Using qPCR, we showed that cells 
exposed to CCA expressed significantly lower levels of AR mRNA than the untreated 
cells (~50% reduction) (Figure 1C).  An important difference between the LAPC4 and 
LNCaP cell lines is that LAPC4 cells express wild-type AR, while LNCaP cells express a 
mutant allele of the AR (T877A). Whereas AR mRNA expression was comparable in both 
cell lines treated with CCA (Figure 1C), our results showed significantly lower AR protein 
expression levels in LNCaP cells (Figure 1B), suggesting that the mutant AR was less 
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stable after CCA exposure.  Together, these results indicate that V-ATPase function is 
required for AR expression and link V-ATPase function to the PSA-AR axis in prostate 
cancer.   
Androgen receptor expression is dependent upon endo-lysosomal pH 
homeostasis. Inhibition of V-ATPase activity disrupts cellular pH homeostasis [2], 
because V-ATPase acidifies the lumen of organelles in the endomembrane system and 
affects cytoplasmic and extracellular pH [1,2]. We used acridine orange staining to 
monitor V-ATPase-dependent pH alterations in acidic organelles. Acridine orange is a 
weak base that accumulates in acidic vesicles and emits fluorescence [38]. As expected, 
both acute treatment (1 hour, Figure 2A) and chronic treatment (24 hours, Figure 2B) 
with CCA decreased acridine orange accumulation in these organelles, suggesting that 
organelle acidification is defective upon V-ATPase inhibition in LAPC4 and LNCaP cells. 
To quantify the pH in these organelles, we used the pH-sensitive fluorescent dye, 8-
Hydroxypyrene-1,3,6-trisulfonic acid (HPTS). HPTS enters the cell by endocytosis and 
accumulates in endosomes and lysosomes [39,40]. The endo-lysosomal pH of both 
LAPC4 and LNCaP cells exposed to 1 hour of CCA treatment was significantly increased 
as compared to the untreated cells (6.55 ± 0.14 to 7.06 ± 0.13 in LAPC4 cells; 6.61 ± 0.07 
to 7.13 ± 0.07 in LNCaP cells) (Figure 2C).  
Chloroquine (ChQ) is a lysosomotropic amine that accumulates in acidic vesicles 
and increases the endo-lysosomal pH [41]. We treated our PCa cell lines with 50 µM 
ChQ to determine if aberrant pH homeostasis inhibits AR expression independently of 
V-ATPase. This dose of ChQ does not compromise cell survival (Supplemental Figure 1). 
Acridine orange staining was comparable in cells treated with 50 µM of ChQ and those 
cells treated with 10 nM CCA (Figure 2A-B). Compared to control, the endo-lysosomal 
pH significantly increased (to 6.79 ± 0.06 in LAPC4 cells and to 7.02 ± 0.06 in LNCaP 
cells) after treatment with ChQ (Figure 2C). Notably, addition of 50 µM ChQ decreased 
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AR mRNA (Figure 2D) and AR protein levels (Figure 2E).  These results indicate that the 
reduction in AR expression following V-ATPase inhibition likely results from aberrant pH 
homeostasis rather than a direct effect of V-ATPase itself. These results also specifically 
link endo-lysosomal organelle pH to AR expression in prostate cancer cells. To our 
knowledge, this is the first report that links AR expression with endo-lysosomal pH 
homeostasis. 
V-ATPase inhibition impairs androgen receptor gene transcription. In an 
attempt to explain our noted decrease in AR expression, we determined whether 
treatment with CCA impaired AR mRNA stability and turnover. To accomplish this, we 
measured AR mRNA decay rates in LAPC4 and LNCaP cells treated with 10 nM CCA in 
the presence of the transcription inhibitor actinomycin D (5 µg/ml) [42,43]. CCA 
treatment did not enhance the AR mRNA decay rate (LAPC4: control = -0.01730 ± 
0.003565 hours vs. CCA = -0.01536 ±0.003021 hours; LNCaP: control = -0.02611 ± 
0.004625 hours vs. CCA =-0.01333 ± 0.001572 fours) (Figure 3). Mann-Whitney analysis 
of AR mRNA decay rates showed that modest differences between control and CCA 
treatment were not statistically significant (LAPC4: p = 0.8; LNCaP: p = 0.1) (Figure 3B). 
We concluded that AR mRNA degradation was not stimulated by CCA treatment, and V-
ATPase inhibition likely impairs transcription of the AR gene. 
HIF1α protein levels and translocation to the nucleus increase when V-
ATPase is inactive.  
Transcription of the AR is tightly controlled. One pathway regulating AR gene expression 
involves the α subunit of the Hypoxia Inducible Factor-1 (HIF-1α) transcription factor 
[44–47].  HIF-1α has been reported to repress transcription of the estrogen hormone 
receptor, ER [48]. Since V-ATPase inhibition was reported to increase HIF-1α protein 
levels in several other cancer cell lines [49,50], we asked whether V-ATPase inhibitors 
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affect HIF-1α expression and stability in prostate cancer cells and whether HIF-1α may 
link V-ATPase and AR.  
To determine if CCA treatment alters HIF-1α expression, we first monitored HIF-
1α protein levels. We analyzed whole cell lysates from LAPC4 and LNCaP cells treated 
with 10 nM CCA for 24 hours. Western blots showed more HIF-1α in cells exposed to 
CCA than in untreated control cells (Figure 4A). Notably, HIF-1α mRNA levels did not 
significantly change upon treatment with CCA (Figure 4B). These results suggest that V-
ATPase inhibition enhances HIF-1α protein translation and/or stability and not HIF-1α 
transcription.  
When active, HIF-1α translocates to the nucleus to act as a transcription factor 
[32,34,51]. We noted higher levels of HIF-1α nuclear localization in CCA-treated cells as 
compared to cells exposed to vehicle control (Figure 4C). Our results suggest that V-
ATPase inhibition induces HIF-1α translocation to the nucleus. 
Loss of V-ATPase activity disrupts iron homeostasis and reduces 
downstream HIF-1α hydroxylation and degradation, leading to decreased 
androgen receptor expression.  The observation that HIF-1α levels increase in the 
presence of CCA could be explained if V-ATPase inhibition prevents HIF-1α degradation.  
Under normoxic conditions, HIF-1α is rapidly turned over by a process that involves HIF-
1α hydroxylation by the VHL ubiquitin ligase, which targets HIF-1α for degradation by 
the proteasome [32,34]. VHL ubiquitin ligase requires iron as a co-factor [32,34], and 
notably, V-ATPase inhibition decreases endocytosis of the transferrin receptor (TfR) [11], 
thus lowering intracellular iron concentrations [52,53].  
In this study, exposure of PCa cell lines to CCA increased intracellular TfR signal 
compared to control (Figure 5A, green), suggesting that when V-ATPase is inactive, TfR 
accumulates in intracellular vesicles and endocytosis of iron is likely impaired. We 
31 
 
 
 
hypothesized that these low intracellular iron concentrations would inactivate VHL 
ubiquitin ligase, thus reducing HIF-1α hydroxylation and increasing HIF-1α stability and 
activity. To test our hypothesis, we attempted to use iron to rescue the HIF-1α-related 
phenotypes in PCa cells lacking V-ATPase. LAPC4 and LNCaP cells were treated with 10 
nM CCA and 500 µM iron (III) citrate separately or simultaneously for 24 hours, and 
whole cell lysates were analyzed via immunoblot (Figure 5B). Cells treated with iron 
alone mimicked untreated control cells. Cells treated with CCA alone showed increased 
levels of HIF-1α that correlated with decreased levels of hydroxylated HIF-1α compared 
to control. Iron rescued the effects of CCA on total HIF-1α protein and hydroxylated HIF-
1α, indicating that normal HIF-1α turnover requires proper iron homeostasis, and V-
ATPase inhibition disrupts this process. Iron also partially rescued AR gene expression in 
CCA-treated cells (2.3 times higher expression in LAPC4 cells and 2.4 times higher 
expression in LNCaP cells compared to CCA-treated cells without iron) (Figure 5B). These 
results indicate that HIF-1α acts as a transcriptional repressor of the AR gene in prostate 
cancer cell lines lacking V-ATPase activity. 
Notably, treatment with iron did not rescue CCA-induced endo-lysosonal pH 
defects.  Both cells treated with CCA alone and cells treated with CCA and iron (III) 
citrate together showed significantly elevated endo-lysosonal pH when compared to 
vehicle-treated control (Figure 5C). Thus, iron restores a step in the V-ATPase-to-AR 
pathway that is downstream of V-ATPase-mediated pH alterations. 
We also asked whether preventing degradation of HIF-1α independently of V-
ATPase would inhibit AR expression. Dimethyloxalylglycine (DMOG) is a cell permeable 
prolyl-4-hydroxylase inhibitor, which prevents HIF-1α hydroxylation and its subsequent 
degradation [54,55]. We hypothesized that treatment with DMOG would mimic CCA-
induced iron depletion and would thus increase HIF-1α protein levels and decrease AR 
expression. Indeed, after addition of DMOG, expression of AR mRNA (Figure 6A) and AR 
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protein levels (Figure 6B) were reduced compared to control, while HIF-1α protein levels 
increased (Figure 6B).  These changes were comparable to those induced upon 
treatment with CCA, confirming that the down-regulation of AR transcription seen 
during V-ATPase inhibition occurs via reduced hydroxylation and increased stabilization 
of HIF-1α. 
2.5. Discussion 
This study identified a novel downstream effector of V-ATPase in prostate cancer 
cells; our results show for the first time that androgen receptor expression is V-ATPase 
dependent (Figure 1), and we present a cellular mechanism that links V-ATPase to AR 
expression and activity (Figure 7). To summarize, loss of V-ATPase activity causes 
alkalinization of endo-lysosomal compartments (Figure 2). This disrupted pH 
homeostasis negatively affects TfR endocytic trafficking (Figure 5) [2,11], leading to 
reduced iron uptake [56]. Under low intracellular iron concentrations, HIF-1α 
hydroxylation is blocked (Figure 5), thus increasing its stability and function. HIF-1α is 
then free to translocate to the nucleus and down-regulate AR gene expression (Figures 
4-6). 
The most intrinsic function of V-ATPase is its ability to acidify intracellular 
compartments [1,2]. Indeed, we demonstrated that during V-ATPase inhibition, it is 
these general pH alterations that mediate AR repression, rather than a V-ATPase-specific 
signaling pathway (Figure 2). Iron availability is a prime candidate effector pathway 
downstream of pH. In support of this hypothesis, TfR accumulates intracellularly after V-
ATPase inhibition in PCa cells (Figure 5A), and aberrant TfR endocytic recycling results in 
iron depletion in several other cell lines [56,57]. In the current study, we demonstrated 
that treatment with iron partially rescues AR expression in cells where V-ATPase is 
inhibited (Figure 5B). However, iron does not rescue the endo-lysosomal alkalinization 
(Figure 2 and 5C) or the defective TfR localization (data not shown) in CCA-treated cells. 
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Thus, iron restores AR expression at a step downstream of V-ATPase–mediated luminal 
pH and membrane traffic defects. These findings also suggest that proper iron 
regulation can compensate in the face of disrupted pH elsewhere in the cell, clarifying 
the critical role that iron availability plays in androgen receptor function.  
Specifically, iron appears to play a role in the HIF-1α degradative process (Figure 
5B). HIF-1 is a heterodimer composed of one regulatory α subunit and one β subunit 
[33]. HIF-1β is constitutively expressed, whereas the expression level of HIF-1α 
determines the extent of active HIF-1 (α/β) available to drive expression of pro-survival 
and pro-apoptotic genes [32,51]. HIF-1α expression is maintained in part by regulated 
protein turnover. Prolyl hydroxylases hydroxylate HIF-1α, which can then bind the VHL 
ubiquitin ligase [34,51], thereby targeting HIF-1α for degradation in the proteasome 
[51].   
The HIF-1α hydroxylation reaction requires oxygen as a co-factor [34]. Therefore, 
under normoxic conditions, prolyl hydroxylases are active and HIF-1α is degraded 
rapidly (Figure 7B-C) [32]. In contrast, during hypoxia, HIF-1α cannot be hydroxylated 
and its degradation is blocked. Notably, iron also serves as co-factor for prolyl 
hydroxylase [34], and CCA-treated PCa cells under normoxic conditions display 
decreased HIF-1α hydroxylation and turnover (Figure 5B) and increased HIF-1α 
translocation to the nucleus (Figure 4C); these effects are reversible following iron 
repletion (Figure 5B). Thus, V-ATPase inhibition mimics chronic hypoxia, because the 
resulting lack of intracellular iron constitutively increases HIF-1α, despite adequate 
cellular oxygen levels (Figure 7D-E).  
Treatment of PCa cells with the prolyl hydroxylase inhibitor DMOG mimics the 
effect of V-ATPase inhibition, increasing HIF-1α levels (Figure 6B) and decreasing AR 
expression at both the mRNA (Figure 6A) and protein level (Figure 6B). These findings 
demonstrate the importance of HIF-1α as the effector molecular linking V-ATPase 
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activity and androgen receptor expression in prostate cancer cells. In previous studies, 
V-ATPase inhibitors were shown to increase HIF-1α levels in a different PCa cell line, PC-
3, as well as in other cancers [49,50,57]. Thus, this V-ATPase-HIF-1α pathway is not 
specific to prostate cancer.  Rather, it is likely a general mechanism that can be exploited 
to manipulate HIF-1α levels. However, our studies are the first to link the V-ATPase-HIF-
1α axis specifically to androgen receptor levels in prostate cancer. 
Crosstalk of AR and HIF-1α in PCa has been previously reported [44–47]. 
However, to our knowledge, HIF-1α inhibition of AR gene expression has not been 
reported in the past, although HIF-1α has been shown to repress transcription of the 
CAD gene [58] and the estrogen receptor alpha gene in breast cancer cells [48]. The 
exact mechanism by which HIF-1α acts as a transcriptional repressor is unknown. It is 
possible that HIF-1α directly binds to the AR gene, thus inhibiting its expression. 
Alternatively, a molecule activated by HIF-1α (e.g. p53) may indirectly represses the AR 
[59,60]. Further studies are required to dissect the exact nature of this mechanism.  
 The V-ATPase-dependent decreases in AR expression outlined here are pertinent 
to both androgen-responsive and androgen-resistant PCa cell lines and tumors. LAPC4 
has a wild-type allele of the AR [61], whereas LNCaP is an androgen-sensitive cell line 
that has the T877A mutation in the ligand-binding domain of the AR [62]. This mutation 
has been reported in patients who have been treated with androgen ablation therapies 
[63], and the mutation prevents inhibition of AR activity, conferring resistance to anti-
androgen treatments [22,62]. Notably, in our studies, inhibition of V-ATPase effectively 
blocks expression of the AR-T887A allele in LNCaP cells (Figures 1,2,5). V-ATPase 
inhibitors may thus lead to new treatments relevant for patients that have androgen-
resistant PCa tumors, as V-ATPase inhibition represses AR activity at the transcriptional 
level, overriding any resistance due to protein mutations. 
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Our studies with CCA support previous studies using a second V-ATPase 
inhibitor, bafilomycin (BAA). In those studies, treatment of PCa cells with BAA reduced 
PSA secretion [12], suggesting that AR transcriptional activity was inhibited. Both CCA 
and BAA are precomacolide antibiotics and share the same mechanism of action: these 
V-ATPase inhibitors bind to the Voc subunit of V-ATPase [64]. thereby inhibiting the 
ATP-driven rotation that is necessary for proton translocation across membranes. While 
this class of V-ATPase inhibitors shows promise in repressing AR expression in PCa cells, 
CCA and BAA target all V-ATPases indiscriminately of cell type, tissue, or organ [64], 
leading to detrimental side effects in the patient. Therefore, the development of a new 
generation of V-ATPase inhibitors directed specifically toward tumor tissue is critical for 
improving prostate cancer patient outcomes. 
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2.6. Figures 
 
Figure 1: V-ATPase inhibition represses androgen receptor in prostate cancer cell 
lines. LAPC4 and LNCaP cell lines, which express Androgen Receptor (AR), were exposed 
to vehicle control (0.01% DMSO) or 10 nM of the V-ATPase inhibitor Concanamycin A 
(CCA) for 24 hours.  A. Prostate Specific Antigen (PSA) mRNA levels were evaluated 
using quantitative real time PCR (qPCR). Bars represent the mean PSA mRNA level 
relative to matched control (n = 3) in LAPC4 (blue) and LNCaP (green) cells. B. Western 
blots and densitometry analysis of LAPC4 and LNCaP whole cell lysates were used to 
monitor AR protein levels using β-actin as a loading control; insert shows representative 
western blot. Bars represent the mean AR protein level relative to matched control (n = 
5). C. AR mRNA levels were evaluated using qPCR. Bars represent the mean AR mRNA 
level relative to matched control (n = 3). A-C error bars represent standard error of the 
mean, * indicates p < 0.05, ** indicates p < 0.01 compared to control as determined by 
Student’s t-test.  
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Figure 2: Endo-lysosomal alkalinization is sufficient to reduce androgen receptor 
expression levels. A-B. LAPC4 (top panel) and LNCaP (bottom panel) cell lines were 
plated on glass coverslips, allowed to attach, and then treated with 0.01% DMSO 
(control), 10nM concanamycin A (CCA), or 50 µM chloroquine (ChQ) for 1hr (A) or 24h 
(B). Coverslips were stained with 1 µM acridine orange (green) for 30 minutes and 
analyzed using fluorescent confocal microscopy. DAPI (blue) was used as nuclear 
marker. Scale bar =10 µM. C. LAPC4 and LNCaP cells were incubated with HPTS and 
then treated with 0.01% DMSO (control), 10 nM CCA, or 50 µM ChQ for 1 hour.  Mean 
endosome and lysosome pH is shown ± SE from 5-7 experiments. D. AR mRNA levels 
(n=3) and E. AR protein levels (n=3) were evaluated following treatment with vehicle 
control (0.01% DMSO) or 50 µM ChQ for 24 hours as described in Figure 1B-C. C-E error 
bars represent standard error of the mean, * indicates p < 0.05, ** indicates p < 0.01, *** 
indicates p < 0.001, **** indicates p < 0.0001 compared to control as determined by 
Mann Whitney test (C) or Student’s t-test (D-E). 
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Figure 3. Androgen receptor mRNA degradation is not stimulated by V-ATPase 
inhibition. LAPC4 and LNCaP cell lines were exposed to 5µg/ml actinomycin D and 
0.01% DMSO (control, black circles) or 10 nM CCA (red diamonds), A. Samples were 
collected at 0.5, 2, 4, 8, 10, 12, 20 and 24 hours and AR mRNA levels were monitored via 
qRT-PCR. Data are expressed as percent remaining mRNA at each time point relative to 
time 0. B. Decay rates were calculated as the slope of the lines shown in Figure 3. A-B 
error bars represent standard error of the mean (n=3), n.s. indicates not significant (p > 
0.05) compared to control as determined by Mann-Whitney test. 
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Figure 4: V-ATPase inhibition increases HIF1α protein levels and nuclear 
localization in prostate cancer cell lines. LAPC4 and LNCaP cell lines were exposed to 
vehicle control (0.01% DMSO) or 10 nM CCA for 24 hours.  A. Western blots of whole 
cell lysates were used to monitor HIF-1α protein levels using β-actin as a loading 
control; image shows representative western blot (n ≥3). B. HIF1α mRNA levels were 
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evaluated using qPCR. Bars represent the mean HIF1α mRNA level relative to matched 
control (n = 4). Error bars represent standard error of the mean, n.s. indicates not 
significant (p > 0.05) compared to control as determined by Student’s t-test. C. LAPC4 
(top panel) and LNCaP (bottom panel) cell lines were plated on glass coverslips, allowed 
to attach, and then treated with 0.01% DMSO (control) or 10nM concanamycin A (CCA) 
for 24h.  Coverslips were immunostained with an antibody against HIF-1α, labeled with 
AlexaFluor secondary antibody (red), and analyzed using fluorescent confocal 
microscopy. DAPI (gray) was used as nuclear marker.  Scale bar =10 µM. 
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Figure 5: Iron (III) citrate treatment partially restores HIF-1α hydroxylation and 
androgen receptor expression in the face of V-ATPase inhibition. A. LAPC4 (top 
panel) and LNCaP (bottom panel) cell lines were plated on glass coverslips, allowed to 
attach, and then treated with 0.01% DMSO (control) or 10nM concanamycin A (CCA) for 
24h.  Coverslips were immunostained with an antibody against TfR, labeled with 
AlexaFluor secondary antibody (green), and analyzed using fluorescent confocal 
microscopy. DAPI (blue) was used as nuclear marker.  Scale bar =10 µM. B. LAPC4 and 
LNCaP cell lines were exposed to vehicle control (0.01% DMSO), 10 nM (CCA), 500 M 
Iron(III) citrate (Fe), or CCA and Fe together for 24 hours. Western blots and 
densitometry analysis of whole cell lysates were used to monitor AR, HIF-1α, and 
hydroxylated HIF-1α (OH-HIF1α) protein levels using β-actin as a loading control; image 
shows representative western blot. Bars represent the mean AR protein level relative to 
matched control (n = 3-5). C. LAPC4 and LNCaP cells were incubated with HPTS and 
then treated with conditions described in Figure 5B above for 1 hour.  Bars represent the 
mean endosome and lysosome pH (n=3-5).  B-C error bars represent standard error of 
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the mean, n.s. indicates not significant (p ≥ 0.05), * indicates p < 0.05, ** indicates p < 
0.01, *** indicates p < 0.001, **** indicates p < 0.0001 compared to control as 
determined by) Student’s t-test (B) andMann-Whitney test (C). 
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Figure 6. Stabilizing HIF1α independently of V-ATPase inhibition is sufficient to 
decrease androgen receptor expression. LAPC4 cell lines were exposed to vehicle 
control (0.01% DMSO), 10 nM CCA, 2mM DMOG, or 5mM DMOG for 24-48 hours. A. AR 
mRNA levels were evaluated using qPCR after 48 hours. Bars represent the mean AR 
mRNA level relative to matched control (n = 3). Error bars represent standard error of 
the mean, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001 
compared to control as determined by Student’s t-test. B. Western blots of whole cell 
lysates were used to monitor AR and HIF-1α protein levels using β-actin as a loading 
control; image shows representative western blot (n = 3).    
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Figure 7. Model for V-ATPase inhibition-induced androgen receptor repression. A. 
In control cells, testosterone (T) activates the androgen receptor (AR). This binding 
induces AR phosphorylation and dimerization. AR dimers and can bind to androgen-
response elements (ARE) in the promoter regions of target genes, leading to cell growth, 
cell proliferation, and expression of PSA. B. V-ATPase (pink) generates and sustains the 
pH gradient required for proper receptor-mediated endocytosis. Transferrin Receptor 
(TfR) uses endocytosis to take iron (Fe) into the cell. C. Iron is used as a co-factor in the 
hydroxylation of HIF-1α (HIF-1α-OH), which is then targeted for degradation. D. 
Concanamycin (CCA) treatment inhibits V-ATPase, leading to TfR-vesicle accumulation, 
which decreases cytosolic iron. E. Without iron, HIF-1α cannot be hydroxylated and is 
not degraded. HIF-1α can bind HIF-1β. HIF-1α/β binds to HIF-1 response elements in 
the AR gene promoter, thereby decreasing AR expression. F. Decreasing AR levels slow 
down Pathway A, leading to less cell proliferation and less expression of PSA. 
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Supplemental Figure 1. Experimental doses of concanamycin A and chloroquine do 
not decrease survival of prostate cancer cell lines. LAPC4 cells (blue squares) and 
LNCaP cells (green triangles) were exposed to 0.01% DMSO (control) or different doses 
of A. concanamycin A (CCA) and B. chloroquine (ChQ) for 24 hours, and cell viability was 
assessed using MTT assays. Data are expressed as the live cell fraction at each drug 
concentration relative to control. Error bars represent standard error of the mean (n=3). 
Red arrows indicate the 10 nM CCA and 50 µM ChQ doses used in these studies.  
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                      3.1. Abstract  
                      Vacuolar ATPases (V-ATPases) comprise specialized and ubiquitously 
distributed pumps that acidify intracellular compartments and energize membranes. To 
gain new insights into the roles of V-ATPases in prostate cancer (PCa) we studied the 
effects of inhibiting V-ATPase pumps in androgen-dependent (LNCaP) and androgen-
independent (C4-2B) cells of a human PCa progression model. Treatment with 
nanomolar concentrations of the V-ATPase inhibitors bafilomycin A or concanamycin A 
reduced the in vitro invasion in both cell types by 80%, regardless that V-ATPase was 
prominent at the plasma membrane of C4-2B cells and only traces were detected in the 
low-metastatic LNCaP parental cells. In both cell types intracellular VATPase was 
excessive and co-localized with prostate-specific antigen (PSA) in the Golgi 
compartment. V-ATPase inhibitors reversibly excluded PSA from the Golgi and led to the 
accumulation of largely dispersed PSA-loaded vesicles of lysosomal composition. 
Inhibition of acridine orange staining and transferrin receptor recycling suggested 
defective endosomal and lysosomal acidification. The inhibitors, additionally, interfered 
with the AR-PSA axis under conditions that reduced invasion. Bafilomycin A significantly 
reduced steady-state and R1881induced PSA mRNA expression and secretion in the 
LNCaP cells which are androgen-dependent, but not in the C4-2B cells which are 
androgen ablation-resistant. In the C4-2B cells, an increased susceptibility to V-ATPase 
inhibitors was detected after longer treatments, as proliferation was reduced and 
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reversibility of bafilomycin-induced responses impaired. These findings make VATPases 
attractive targets against early and advanced PCa tumors. 
3.2. Introduction 
Vacuolar adenosine triphosphatases (V-ATPases) are protein complexes that use 
the energy of ATP hydrolysis to pump protons across endosomal and lysosomal 
membranes 1. The luminal acidic pH generated by V-ATPases facilitates processes such 
as protein sorting and secretion, receptor recycling, endocytosis, and protein 
degradation 2–6. Plasmalemmal V-ATPases present in cells specialized for active proton 
secretion, including cancer cells, pump protons to the extracellular space. They sustain 
the low pH that activates the extracellular metalloproteases, allowing for tumor cell 
motility, proliferation, and metastasis 7–10. Accumulated evidence have shown V-ATPase 
involvement in tumor invasion and multi-drug resistance in breast cancer 11–14, oral 
squamous cell carcinoma 15, 16, hepatocellular carcinoma 8, melanoma 17, pancreatic 
cancer 9, and PCa 18. Additional information regarding the functions of V-ATPases in PCa 
is limited; Iejimalide B, an inhibitor of V-ATPases, induces cell cycle arrest and apoptosis 
in prostate cancer (PCa) cells 19. 
PCa is the second most common cancer in men in the United States. PCa 
screening is performed by testing the serum levels of the biomarker prostate-specific 
antigen (PSA), an androgen-dependent 20 serine protease secreted by both healthy and 
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cancerous prostate tissue 21. PSA expression is under control of the androgen receptor 
(AR). The AR is activated by binding of dihydrotestosterone, which facilitates formation 
of dimers that are subsequently relocated to the nucleus 22. Nuclear AR is a transcription 
factor that binds androgen response elements in the promoter region of PSA and other 
target genes 23. Increased PSA serum levels correlate to an extent with aggressiveness of 
the cancer and unfavorable outcome for PCa patients 20,21, 24. Localized (androgen-
dependent) PCa is treated by combining androgen ablation and radiation therapies 
which initially successfully reduces tumor growth and progression. However, androgen 
ablation-resistant disease eventually develops, where cancer cells have adapted to low 
androgen levels and have elevated invasive capacity. This poses a major clinical 
challenge to reduce high lethality rates from metastatic tumors and cancer recurrence 
after prostatectomy 25. 
In this study, the effects of V-ATPase inhibitors on PCa invasion and PSA biology 
were investigated. We used the LNCaP → C4-2B cell model of PCa progression that 
mimics the advancing disease from androgen-dependency to androgen ablation-
resistance 26. We showed that PSA is down-regulated (reduced mRNA and secretion) by 
inhibiting V-ATPases in the LNCaP cells regardless of the presence of R1881, suggesting 
that V-ATPase inhibitors interfered with the AR-PSA axis. Unlike the LNCaP cells, PSA 
expression and secretion were not altered in the androgen-independent C4-2B cells in 
spite of a dramatic reduction of the in vitro invasion of both cell types. Both cell types 
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show an extensive distribution of intracellular V-ATPase pumps, but a distinctive 
distribution at the plasma membrane. Plasma membrane V-ATPases were abundant in 
the C4-2B cells, which are also more susceptible to V-ATPase inhibitors. Together these 
findings make V-ATPase pumps attractive targets against early and advanced PCa 
tumors. Combined with other therapies, V-ATPase inhibitors could help prevent 
transformation into the castration-resistant phenotype. 
3.3. Materials and methods 
Cell culture. LNCaP and PC-3 cells (both from ATCC, Manassas, VA, USA) and C4-2B 
cells (kind gift from Prof. Dr. George N. Thalmann) were cultured in T-medium (DMEM, 
Sigma Aldrich, St. Louis, MO, USA; 20% F12 nutrient mixture, 5 µg/mL insulin, 25 µg/mL 
adenine hydrochloride, 10 µg/mL transferrin, 0.25 µg/mL biotin, 15 pg/mL 
trijodothyronine, 100 U/mL penicillin/streptomycin) supplemented with 10% FBS. Cells 
were maintained at 37°C and 5% CO2 in a humidified atmosphere. Media was routinely 
changed every 2–3 days, and cells passaged at 80–90% confluency. 
Antibody generation. The polyclonal antibody to V-ATPase was developed against the 
peptide N-I162KHKIMLPPRNRGT175-C of the subunit V1A by BioGenes (Berlin, Germany). 
Single peptides were used for the immunization of 2 rabbits over 35 days. The animals 
were intramuscularly immunized using BioGenes' adjuvant mixed 2:1 with the V1A 
antigen. Parts of the sera were affinity purified against the peptide that was used for 
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immunization. Antibodies were tested for specificity by performing BLAST alignment 
searches and by Western blotting and immunocytochemistry experiments. 
Immunocytochemistry. Cells were fixed with 4% paraformaldehyde for 10 min at RT 
and cell membranes permeabilized with 0.02% TritonX-100 in PBS. Cells were blocked 
with 5% GS-PBS for 30 min at RT. Incubation with primary antibodies was performed at 
1:100 dilution in 5% GS-PBS for 1 h at RT (LAMP-1, LAMP-2, clathrin, Na+K+-ATPase, 
Giantin antibodies: Abcam, Cambridge, MA, USA; AR and transferrin receptor/TR 
antibodies: Invitrogen). Cells were washed with PBS and incubated for 30 min with the 
secondary fluorescent antibodies (AF488 and AF546, Invitrogen; 1:500 in 5% GS-PBS). 
Cells were washed with PBS and mounted onto microscope slides in mounting media. 
Primary and secondary antibody controls were included for all immunostaining 
experiments. For acridine orange staining, cells were incubated for 30 min at 37°C with 1 
µM acridine orange diluted in cell culture medium and fixed with paraformaldehyde as 
described above. Slides were analyzed with the Zeiss LSM510 confocal system.Line 
profiles of fluorescent intensity were obtained using ZEN 2009 Light Edition © Carl Zeiss 
MicroImaging software 
Plasma membrane isolation. Plasma membrane fractions were obtained by Percoll 
density gradient centrifugation as described before 27. 
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RNA isolation and cDNA synthesis RNA was isolated from cells grown in multiwell 
plates with the RNeasy Mini kit (Qiagen, Germantown, MD, USA), following the 
manufacturer’s instructions using the QIAshredder (Qiagen) to homogenize cell lysates. 
Complimentary DNA was synthesized from 2,000 ng RNA with the RETROscript® cDNA 
kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
instructions. 
Quantitative realtime PCR (qRT-PCR) Specific primers were designed against V-
ATPase subunits, PSA, and TATA-binding protein (TBP) as an internal standard; primer 
sequences are listed in Table S1. The SYBR Green I Mastermix (Roche, Indianapolis, IN, 
USA) was used for the following PCR conditions: denaturation at 95°C for 10 min, 
followed by 40 cycles of: 30 s at 95°C, 30 s at 65°C, and 20 s at 72°C. qRT-PCR was 
performed on the Roche LightCycler480 instrument. 
Western blotting. Whole cell lysates were obtained by incubating cells for 10 min on 
ice with lysis buffer (25 mM Tris, 8 mM MgCl2, 1 mM DTT, 15% glycerol, 1% TritonX-100, 
protease inhibitor cocktail). Insoluble cell debris was removed by centrifugation of 
lysates at 13,000 rpm for 10 min at 4°C. The protein concentration was determined by 
bicinchoninic acid assay (Pierce, Rockford, IL, USA) against a BSA standard curve. 80 µg 
total protein were analyzed by SDS-PAGE and immunoblotted with primary antibodies 
overnight, followed by incubation and detection with secondary HRP-conjugated 
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antibodies (Invitrogen). Densitometry quantification of western blot bands was 
performed using ImageJ software. 
Cell treatments and PSA secretion. Cells were incubated for 24 h with culture media 
containing 5% charcoal-treated FBS to deplete cells of androgens and then incubated 
for 24 h or 48 h with 10 nM bafilomycin A (Baf.A), 10 nM R1881, or both, in T-media 
supplemented with 1% charcoal-treated FBS. RNA isolation, RT-PCR, Western blotting 
and immunostaining were then performed as described above. PSA secreted into the 
cell culture media was quantified using an ELISA kallikrein 3/PSA kit (R&D Biosystems) 
according to the manufacturer’s instructions. 
Invasion and proliferation assays. Invasion Matrigel invasion assays were performed 
according to the manufacturer’s instructions (BD Biosciences, San Jose, CA, USA). LNCaP 
and C4-2B cells were seeded for ~40 hours before treatment. Cells in invasion chambers 
were treated for 24 h with 10 nM Baf.A, then excess cells were removed with a cotton 
swab from the top of the chamber, invaded cells were fixed in methanol for 2 min and 
stained with Toluidine Blue for 2 min. Inserts were excised, mounted in immersion oil, 
and counted under the microscope. Proliferation. LNCaP and C4-2B cells were treated 
with 10 nM Baf.A or Conc.A (24 h or 48 h) and cell proliferation measured with the MTT 
cell proliferation assay kit (ATCC) by reading absorbance at 570 nm. 
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Statistical analysis. Student’s t-tests were performed to determine statistically 
significant differences in V-ATPase subunit mRNA expression levels between cell lines, 
and in mRNA and secretion levels after treatments, using GraphPad Prism 4 software. 
3.4. Results 
Two PCa epithelial cell models with different invasiveness potential were 
compared to study the effects of V-ATPase inhibitors on PCa cell invasion and PSA 
biology. We measured the in vitro invasion of the poorly invasive, LNCaP, and highly 
invasive, C4-2B, human PCa cells treated with bafilomycin A (Baf.A) and Concanamycin A 
(Conc.A), two highly potent (IC50 1–10 nM) and specific V-ATPase inhibitors 28, 29. V-
ATPase inhibitors are known to reduce the in vitro invasion of highly invasive human 
breast cancer cells, which express V-ATPases at the cell surface, but no the invasion of 
the poorly invasive cell lines, which do not express plasmmalemal V-ATPases 11. 
The V-ATPase inhibitors prevented in vitro invasion of both human PCa cells, 
LNCaP and C4-2B, by about 80 % (Fig. 1B,D) under conditions where proliferation was 
not compromised (10 nM Baf.A or Conc.A for 24 hours) (Fig. 1A,C). However, after 48 
hours of treatment, proliferation of the highly invasive C4-2B cells was significantly 
reduced (Fig. 1A,C). Suppression of the in vitro invasion of both PCa cells could be 
explained if the poorly invasive and highly invasive cells express V-ATPases at the cell 
surface, as the hallmark of V-ATPase pumps in cancer biology is their specialized role at 
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the plasma membrane where V-ATPases facilitate extracellular acidification and 
invasion 5, 9, 11, 12, 30, 31. 
We made an antibody against the V-ATPase subunit V1A to study V-ATPase 
cellular distribution. Subunit V1A does not have isoforms and is therefore a component 
of every V-ATPase complex assembled in the cell. Western blots of whole cell lysates 
revealed one major band that migrated at about 70-kDa, the molecular mass of subunit 
V1A (Fig. 2A) 2, 7. Treatment with the peptide antigen competed labeling, validating the 
antibody’s specificity for subunit V1A. Plasma membrane fractions isolated from the 
poorly invasive LNCaP cells had only trace amounts of V-ATPase subunit V1A, and V1A 
was not detectable at the plasma membrane by immunofluorescence in these cells (Fig. 
2C). Immunoblots showed V1A present at the plasma membrane of the highly invasive 
C4-2B cells (Fig. 2B) but at lower levels than the plasma membrane protein Na+K+-
ATPase. Thus, like other cancer cells, expression of V-ATPase pumps at the plasma 
membrane correlates with an increased invasive phenotype in PCa cells. 
Suppression of invasion after treating LNCaP cells with Baf.A and Conc.A 
considering that have elfin amounts of plasmalemmal V-ATPases (Fig. 2B) suggests 
novel roles for intracellular V-ATPases that can influence the invasive phenotype of 
androgen-dependent PCa cells. Co-immunostaining with the anti-V1A antibody and 
antibodies to subcellular markers showed the intracellular V-ATPase pumps distributed 
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throughout the endomembrane system of LNCaP (Fig. 2C) and C4-2B cells (Fig. S1). V-
ATPase signal was predominant in the Golgi compartment (Fig. 2D); the Golgi tether 
protein giantin completely co-localized with V-ATPase in both cell lines. PSA was 
abundant in the Golgi compartment and notably, we showed that PSA completely to co-
localize with Golgi V-ATPase (Fig. 2D). V-ATPase in the Golgi and peri-Golgi regions was 
positive also for endosomal proteins such as clathrin and tranferrin receptor, and partly 
overlapped with the lysosomal marker LAMP-1 (Fig. 2C). 
V-ATPase function is necessary for protein trafficking across endocytic and 
secretory pathways 6, 32; thus, we anticipated PSA trafficking from the Golgi and its 
secretion to be V-ATPase dependent. Because PSA expression and secretion are induced 
by androgen 22, we measured PSA secretion from the androgen-dependent LNCaP cells 
after 24 and 48 hours exposure to R1881, a dihydrotestosterone analogue, which 
stimulates androgen receptor-mediated PSA secretion; and after exposure to Baf.A to 
block V-ATPase function. As expected, secretion of PSA was stimulated by a saturating 
concentration of R1881 (10 nM) (Fig. 3A), and both basal and R1881-induced PSA 
secretion were decreased in the presence of Baf.A. 
In addition to suppressing PSA secretion, V-ATPase inhibitors disturbed PSA 
recruitment in the Golgi compartment. Treatment with Baf.A (Figs. 3B, 4A,B) or Conc.A 
(Fig. S2) for 16 hours and up to 48 hours excluded PSA from the Golgi. PSA became 
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dispersed in discrete vesicles throughout the cell, whereas V-ATPase remained in the 
Golgi (Fig.S3). This response was observed in the LNCaP and C2-4B cells alike (Fig. 4A,B), 
and therefore was independent of the invasive potential of the PCa cells. Removal of 
Baf.A from the media restored compartmentalization of PSA with V-ATPase in the Golgi 
of the LNCaP cells (Fig. 4A), in line with the notion that PSA recruitment into the Golgi 
required active intracellular V-ATPases. In the highly invasive C4-2B cells, reversibility 
was detected at 16 hours (Fig. 4B), but was impaired after 48 hours incubation with the 
V-ATPase inhibitor. Susceptibility of the C4-2B cells to Baf.A and Conc.A treatments was 
also evident in the proliferation assays after 48 hours (Fig. 1B). 
The dispersion of PSA was detected after administrating Baf.A alone or in 
combination with R1881 (Fig. 3B). R1881 alone did not disturb PSA 
compartmentalization in the Golgi regardless that R1881 enhanced PSA secretion, 
indicating that Baf.A-induced formation of PSA-containing vesicles differed from normal 
PSA secretory events. Treatment with V-ATPase inhibitors likely targeted PSA for 
lysosomal degradation via autophagy-independent processes, because: 1) vesicles 
containing PSA were positive for the lysosomal markers LAMP1 and LAMP2 (Fig. 4C); 2) 
the autophagic LC-3-positive vesicles were observed as distinct punctae (Fig. 4C); 3) the 
ratio LC-3I/LC3II was unchanged, as assessed by Western blots (not shown); and 4) PSA-
containing vesicles did not form under conditions that block autophagy (100 nM Baf.A, 
2 hours) (Fig. S4) 33. 
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The fact that V1A is absent in the lysosomal PSA-containing vesicles suggests that 
the organelles were not acidified and degradation events impaired. Accordingly, V-
ATPase inhibitors prevented vesicle staining with acridine-orange, therefore supporting 
the idea that endosomal and lysosomal acidification are defective (Fig. 5A). In addition, 
transferrin receptor recycling to the cell surface was blocked, as indicated by its 
retention in the Golgi with V-ATPase pumps in the Baf.A-treated cells (Fig. 5B), 
suggesting that cell-surface transport is disrupted upon V-ATPase inhibition. Finally, 
total intracellular PSA was significantly greater when R1881 was added in the presence 
of Baf. A (Fig. 5C), suggesting that PSA is not degraded when V-ATPase function is 
inhibited. 
We measured PSA transcripts levels by qRT-PCR and determined that basal PSA 
was down-regulated at the transcriptional level in the poorly invasive androgen-
dependent LNCaP cells treated with Baf.A. PSA mRNA decreased by 1.8- and 2.6-fold at 
24 and 48 hours incubations with Baf.A (Fig. 6A). In addition to lowering PSA at steady-
state, Baf.A dramatically suppressed R1881-induction of PSA, suggesting that V-ATPase 
inhibition interferes with AR transcriptional activity. A more modest decreased of AR 
protein was observed in the LNCaP cells after treatment with Baf.A for 48 hours in the 
presence (induced state) and absence (steady state) of R1881 (Fig.6B). PSA secretion, 
PSA expression, and AR protein were not reduced in the C4-2B cells by Baf.A after 24 
hours (Fig. 6C), when invasion significantly declined (Fig. 1D). These results attribute 
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increasingly important roles to plasma membrane-associated V-ATPase pumps in the 
highly invasive PCa cells, whereas intracellular V-ATPase pumps appear to be primarily 
responsible for defective PSA expression and secretion and reduction of invasion 
triggered by Baf.A and Conc.A in the LNCaP cells. 
3.5. Discussion 
This study revealed important new roles for V-ATPase pumps in PCa cells. 
Pharmacological inactivation of V-ATPase interferes with the AR-PSA axis. It reduces PSA 
secretion and PSA mRNA expression in the androgen-dependent LNCaP cells. Together 
with a dramatic reduction (by 80%) of the in vitro invasion of LNCaP (poorly invasive) 
and C4-2B (highly invasive) cells, these findings make V-ATPase pumps attractive new 
targets against early and advanced PCa tumors. In this study, we used Baf.A at its 
IC50concentration (10 nM) to avoid any secondary and unspecific effects 34 and 
reproduced our studies using Conc.A, another V-ATPase inhibitor for which V-ATPase is 
the only known target, arguing against a general toxic effect independent of V-ATPase 
inhibition. 
The link of plasma membrane-associated V-ATPases and invasion of high-
metastatic cells has been broadly disseminated 5, 9, 11–13. Our findings indicate that 
intracellular V-ATPases also contribute to the invasive phenotype of PCa cells because 
the low-metastatic androgen-dependent LNCaP cells have only traces of V-ATPase 
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pumps at the cell surface and excessive intracellular V-ATPase pumps. It has been shown 
that Golgi associated intracellular V-ATPases are necessary for Golgi functions 35 and 
that V-ATPases in endosomal and lysosomal compartments support protein trafficking 
and degradation in all eukaryotic cells 2, 4, 5, 6. In this context, PCa cells are not different. 
V-ATPase inhibitors decrease PSA secretion and recycling of the transferrin receptor to 
the plasma membrane. They also lead to accumulation of PSA-loaded vesicles of 
lysosomal nature (LAMP-1 and LAMP-2 positive), which could be degradative or 
secretory lysosomes. Since the catalytic subunit of the V-ATPase complex (V1A) is absent 
from the PSA-loaded vesicles, we expected luminal acidification to be impaired. A 
defective endosomal and lysosomal acidification can help explain the membrane 
trafficking defects; and it is supported by absence of acridine orange staining in Baf.A 
and Con.A treated cells. 
The scope of V-ATPase in PCa physiology extends beyond the boundaries of the 
organelles where they are present. V-ATPase inhibitors suppress androgen responses 
such as R1881 induction of PSA mRNA expression in the androgen-dependent LNCaP 
cells, but not in the C4-2B cells that have developed androgen resistance. One 
explanation to how V-ATPase inhibitors reduce PSA mRNA is that by excluding PSA 
from the Golgi and redistributing it into the lysosomal vesicles, V-ATPase inhibitors 
activate a negative feed-back loop and PSA expression is decreased. Time course 
analysis of PSA mRNA expression levels (not shown) support this model. PSA vesicle 
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formation is detected at least at 16 hours treatment and precedes PSA mRNA down-
regulation, which is detected only after 24 hours. It has been shown that V-ATPase 
inhibition lowers the cytosolic pH 11. An aberrant cytosolic pH can interfere with the AR-
PSA axis, and we will expect other cellular processes to be defective too. Any cytosolic 
pH defect will be more drastic in the C4-2B cells where the plasma membrane-
associated V-ATPase pumps are more abundant. 
The isogenic nature of the LNCaP and C4-2B cell lines and their resemblance to 
androgen-ablation resistant progressive disease 26 allow us to compare cellular events 
associated with V-ATPase function in progressively invasive PCa cells. Our results 
revealed an increasing importance of V-ATPase in the metastatic C4-2B PCa cells. The 
C4-2B cells express significantly more V-ATPase pumps at the cell surface and many 
Vo subunit isoforms are upregulated (Table S2) relative to LNCaP (up to 9-fold) and to 
non-cancerous (up to 60-fold) prostate cells. Additionally, V-ATPase inhibitors suppress 
proliferation in the C4-2B cells (48 hours incubation) and Baf.A-induced responses 
become irreversible over time. 
Future work will focus on identifying the V-ATPase subunit isoforms directly 
involved in PCa invasion, and suppression of PSA expression and secretion to selectively 
target prostate tumors in vivo. Baf.A and Conc.A do not discriminate between V-ATPase 
isoforms 28, 29, although the V-ATPase complex comprises multiple subunit isoforms 
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which combine to yield tissue- and organelle-specific V-ATPase pumps 6, 7. Our 
attempts at siRNA-mediated knockdown V1A resulted in lower mRNA expression (up to 
70%) but stable V1A protein expression (not shown). Obviously, knockdown of subunit 
isoforms of large multisubunit complexes such as V-ATPase is not trivial; targeting of 
multiple subunits simultaneously may be necessary to reach inactivation levels 
comparable to the V-ATPase inhibitors. 
The AR in LNCaP cells carries the mutation T877A in the ligand-binding 
domain 36, 37 which is equally distributed in those patients who have received 
hydroxyflutamide or bicalutamide therapy 38. This clinically relevant mutation prevents a 
blockade of receptor function by most anti-androgen therapies in LNCaP cells 36, 37. 
Therefore, V-ATPase inhibitors may result in important clinical benefits for patients 
expressing anti-androgen resistant mutations such as T877A. In the long-term, 
responsiveness of tumor cells to V-ATPase inhibitors might be used to control and 
prevent prostate tumor metastases. V-ATPase inhibitors may also help distinguish 
androgen-dependent and -independent tumor cells, as PSA secretion and mRNA 
expression are reduced only in the androgen-dependent cells (LNCaP cells). Combined 
with other therapies, V-ATPase inhibitors could additionally help prevent transformation 
into the castration-resistant phenotype. 
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3.6. Figures 
 
 
Figure 1. Effect of V-ATPase inhibitors on cell proliferation and in vitro invasion of 
PCa cells. Baf.A and Conc.A prevents invasion of LNCaP and C4-2B cells. Poorly invasive 
LNCaP (A, B) and highly invasive C4-2B (C, D) cells were treated with Baf.A or Conc.A (10 
nM) for 24 hours or 48 hours. Proliferation (A, C) was measured with the MTT cell 
proliferation assay and invasion (B, D) with a Matrigel invasion assay. N.S., not 
significant; *, p<0.05; **, p<0.01; significance levels relative to untreated control. 
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Figure 2. Cellular distribution of V-ATPase in PCa cells. (A) Peptide antibody 
specificity for subunit V1A. Western blot of whole cell lysates from the LNCaP cells were 
probed with anti-V1A antibody in the presence and absence of its peptide antigen (10 
µM). The same membrane was probed with β-actin (loading control). Antibody (6 ug) 
and peptide (60ug) were incubated 24 hours at 4°C (wells 4 &5) or 2 hours at RT (wells 5 
&6). Lanes 1, 3, and 5 (20 µg protein); Lanes 2, 4, and 6 (50 µg protein). (B) Plasma 
membrane fractions from LNCaP and C4-2B cells. The same gel was proved with the 
plasma membrane protein Na+K+-ATPase. WCL=whole cell lysate; PM=plasma 
membrane. (C) V-ATPase is present in endosomal and lysosomal membranes of LNCaP 
cells. Cells were co-immunostained with antibodies against the V-ATPase subunit V1A 
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and the indicated marker proteins of the endocytic recycling pathway (transferring 
receptor, clathrin), secretory pathway (clathrin), lysosomes (LAMP-1), and plasma 
membrane (Na,K-ATPase). Proteins were labeled with AlexaFluor secondary antibodies, 
and co-localization analyzed using confocal microscopy determining a line profile of 
fluorescent intensity. (D) V-ATPase and PSA co-localize in the Golgi compartment of PCa 
cells. LNCaP and C-4-2B cells were co-immunostained with anti-V1A, Golgi protein 
giantin, and PSA as described above. Scale bar =10 µm. 
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Figure 3. Effect of V-ATPase inhibitors on R1881-induced PSA secretion and 
cellular distribution. (A) Baf.A treatment reduces PSA secretion. The LNCaP cells were 
incubated with 10 nM Baf.A in the presence and absence of 10 nM R1881 (24 or 48 
hours) or with 0.01% DMSO (Control). The PSA secreted was quantified by ELISA and 
normalized to cell number. (B) Baf.A treatment disturbs PSA recruitment in the Golgi. 
The LNCaP cells treated as described in A were immunostained with antibodies to V1A 
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and PSA and analyzed as described for Figure 2C. ***, p<0.001; **, p<0.01; significance 
levels relative to controls. 
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Figure 4. Formation of lysosomal PSA-loaded vesicles by treatment with inhibitors 
of V-ATPase pumps. (A) PSA vesicle formation is reversible in the LNCaP cells (16 – 48 
hour), (B) but not in the C4-2B cells (48 hours) treated with Baf.A. The LNCaP (A, C) and 
C4-2B (B) cells were incubated with 10 nM Baf.A (16, 24, or 48 hours) or with 0.01% 
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DMSO (Control). The V-ATPase inhibitor was removed by incubation in normal growth 
media for an additional 24 hours (Wash) to restore PSA compartmentalization with V-
ATPase in the Golgi. (C) PSA-containing vesicles have lysosomal composition. The LNCaP 
cells were treated with 10 nM Baf.A (24 hours) or with 0.01% DMSO (Control). (A-C) Cells 
were immunostained with antibodies to V1A, PSA, LAMP1, LAMP2, or LC-3 and analyzed 
as described for Figure 2C. Scale bar =10 µm. 
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Figure 5. Effect of V-ATPase inhibitors on endosomal acidification and trafficking. 
(A) V-ATPase inhibitors disturb endosomal and lysosomal acidification. Cells were 
treated with 10 mnM Baf.A or Conc.A for 24 h, incubated with 1 µM acridine orange, and 
analyzed by confocal microscopy. (B) Transferrin Receptor recycling to the plasma 
membrane is reduced by Baf. A. LNCaP treated with 10 nM Baf.A or 0.01% DMSO 
(Control) for 24 hours were analyzed as described for Figure 2C. (C) Baf.A treatment 
cause intracellular accumulation of PSA. Cells were treated with R1881 and/or Baf.A as 
described for Figure 3A, whole cell lysates analyzed by immunoblots using antibodies 
against PSA and β-actin (loading control), and relative PSA protein levels quantified with 
Image J software (n=3–4). Scale bar =10 µm. **, p<0.01; significance levels relative to 
controls. 
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Figure 6. V-ATPase inhibition interfere with the AR-PSA axis in LNCaP, but not in 
the C4-2B cells. (A) Baf.A treatment reduces PSA mRNA expression in LNCaP cells. Cells 
were treated with 10 nM Baf.A and/or R1881 and PSA mRNA was quantified by qRT-PCR 
using specific primers (Table S1) and expressed as a ratio relative to the internal control 
TATA-binding protein (TBP) (B) Baf.A treatment lower AR protein levels in the LNCaP 
cells. Immunoblots of whole cell lysates were analyzed using antibodies to the AR and β-
actin (loading control) and relative AR protein quantified as described for Figure 5C. (C) 
PSA secretion, PSA expression (mRNA, protein), and AR protein levels are not altered by 
Baf.A in the C4-2B cells. Cells were treated with Baf.A and analyzed as described above 
for B (AR protein), A (PSA mRNA), and for Figures 5C (PSA protein) and 2A (Secreted 
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PSA). Relative protein levels were quantified with Image J software (n=3–4). ***, p<0.001; 
significance levels relative to controls. 
 
 
 
Figure S1. Distribution of Intracellular V-ATPase in C4-2B Cells. V-ATPase is present 
in endosomal and lysosomal membranes of C4-2B cells. Cells were co-immunostained 
with antibodies against the V-ATPase subunit V1A and the indicated marker proteins of 
the endocytic recycling pathway (transferring receptor, clathrin), secretory pathway 
(clathrin), lysosomes (LAMP-1). Proteins were labeled with AlexaFluor secondary 
antibodies, and co-localization analyzed using confocal microscopy.  
 
82 
 
 
 
 
 
Figure S2. The V-ATPase inhibitors Baf.A and Conc.A Alter Golgi 
Compartmentalization of PSA in LNCaP and C4-2B Cells.  Cells were incubated with 
10 nM Baf.A or Conc.A (16 or 24 hours) or with 0.01% DMSO (Control) and co-
immunostained with antibodies against the V-ATPase subunit V1A and PSA. Localization 
was analysed by confocal microscopy. 
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Figure S3. Baf.A Does Disturb with Golgi Compartmentalization of V-ATPase Pumps 
in PCa cells.  LNCaP and C4-2B cells were treated with 10 nM BaF.A or CCA (24 hours) or 
with 0.01% DMSO (Control) and co-immunostained with antibodies against the V-ATPase 
subunit V1A, PSA, and Giantin. Proteins were labeled with AlexaFluor secondary 
antibodies, and co-localization analyzed using confocal microscopy. 
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Figure S4. PSA-Containing Vesicles Do Not Form Under Conditions that Block 
Autophagy. LNCaP cells were incubated with 100 nM Baf.A for 2 hours or with 0.01% 
DMSO (Control) and co-immunostained with antibodies against the PSA and LC-3. 
Localization was analysed by confocal microscopy. 
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Supplementary table S1. Primers used for qPCR 
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Supplementary Table S2.  V-ATPase Vo subunit expression in prostate cells. Vo subunit 
isoform mRNA levels incrementally increase from non-cancerous RWPE-1 prostate cells 
to low invasive LNCaP PCa cells to highly invasive C4-2B PCa cells. RWPE-1 cells were 
cultured in keratinocyte medium supplemented with bovine pituitary extract (0.05 mg/mL) 
and EGF (5 ng/mL). Total RNA was reverse transcribed, subunit expression analyzed by 
qRT-PCR, and expressed as a ratio relative to the internal control TBP. *, p<0.05; **, p<0.01; 
***, p<0.001; N.S= not significant 
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           4.1. Abstract  
The vacuolar ATPase (V-ATPase) proton pump sustains cellular pH homeostasis, 
and its inhibition triggers numerous stress responses. However, the cellular mechanisms 
involved remain largely elusive in cancer cells. We studied V-ATPase in the prostate 
cancer (PCa) cell line PC-3, which has characteristics of highly metastatic PCa. V-ATPase 
inhibitors impaired endo-lysosomal pH, vesicle trafficking, migration, and invasion. V-
ATPase accrual in the Golgi and recycling endosomes suggests that traffic of internalized 
membrane vesicles back to the plasma membrane was particularly impaired. Directed 
movement provoked co-localization of V-ATPase containing vesicles with F-actin near 
the leading edge of migrating cells. V-ATPase inhibition prompted prominent F-actin 
cytoskeleton reorganization. Filopodial projections were reduced, which related to 
reduced migration velocity. F-actin formed novel cytoplasmic rings. F-actin rings 
increased with extended exposure to sublethal concentrations of V-ATPase inhibitors, 
from 24 to 48 h, as the amount of alkalinized endo-lysosomal vesicles increased. Studies 
with chloroquine indicated that F-actin rings formation was pH-dependent. We 
hypothesize that these novel F-actin rings assemble to overcome widespread traffic 
defects caused by V-ATPase inhibition, similar to F-actin rings on the surface of exocytic 
organelles. 
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4.2. Introduction  
Membrane compartmentalization allows eukaryotic cells to organize functions by 
grouping them in membrane bound vesicles.  Compartmentalization is maintained 
through vesicle transport [1–3], which relies upon differential pH gradients [4,5]. Both 
processes require Vacuolar type H+-ATPase (V-ATPase) proton pumps [4,6].  V-ATPase is 
a multisubunit protein complex that comprises two functional domains: V1 and Vo [7,8].  
The catalytic domain (V1) hydrolyzes cytosolic ATP, which powers proton transport via 
the membrane embedded domain (Vo). Active transport of protons by V-ATPase acidifies 
endosomes, lysosomes, Golgi-derived vesicles, clathrin-coated vesicles, and secretory 
vesicles [7–9]. 
V-ATPase proton transport also generates a membrane potential that is 
necessary to activate secondary transport systems [7]. V-ATPase-dependent organelle 
acidification and membrane energization are important in several cellular processes, 
particularly those that rely on membrane trafficking. Receptor- or clathrin-mediated 
endocytosis, endosomal vesicle budding and cargo distribution, protein maturation, and 
lysosome biogenesis require functional V-ATPases [10]. In addition to intracellular V-
ATPases, certain cells specialized for active proton secretion also express V-ATPase at 
the plasma membrane. In clear cells of the epididymis [11], alpha-intercalated cells of 
the kidney [12], and osteoclasts [13], plasmalemmal V-ATPase acidifies the extracellular 
milieu, which is critical for sperm maturation, urine acidification, and bone resorption, 
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respectively.   
In cancer cells, plasma membrane associated V-ATPases have been largely linked 
to cancer migration and invasive phenotypes [14–17]. Cancer tumor cell lines with high 
metastatic potential express more V-ATPase pumps at the plasma membrane than less 
aggressive cell lines [9,15,16,18]. Extracellular acidification by V-ATPase activates 
cathepsin [9,19,20], which is required for cell motility and invasion.  
Their role in metastasis and cell death makes V-ATPase proton pumps attractive 
targets to combat cancer. V-ATPase is involved in angiogenesis. The pigment 
epithelium-derived factor, a potent inhibitor of angiogenesis, was shown to down-
regulate expression of the V-ATPase at the plasma membrane in the lung metastatic CL1 
cell line [21–23]. In addition, the uptake of chemotherapeutic drugs is sensitive to pH 
alterations. V-ATPase facilitates sequestration of chemotherapeutic agents in acidic 
compartments, which contributes to drug resistance [24–27]. Loss of V-ATPase function 
promotes apoptosis by caspase-dependent and independent mechanisms in several 
cancer cell lines [28–34].  
V-ATPase activity is linked to several cellular events in prostate cancer (PCa) cells. 
V-ATPase inhibitors cause PCa cell apoptosis and cell cycle arrest [34].  V-ATPase is 
crucial for normal Prostate-Specific Antigen (PSA) physiology. V-ATPase inhibitors 
suppress PSA expression, alter PSA intracellular distribution, and reduce PSA secretion 
[16]. It has been reported that V-ATPase activity is regulated by the tumor metastasis 
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suppressor gene 1 [35,36] and the pigment epithelium-derived factor [21]. In highly 
aggressive PCa cell lines such as PC-3, V-ATPase is required for delivery of the 
membrane-bound matrix metalloproteinase MMP-14 to the plasma membrane, as well 
as cell growth and invasiveness [18,34].   
We used the prostate adenocarcinoma PC-3 cell line in this study.  PC-3 derived 
from bone metastasis of a human prostate carcinoma and possess many of the 
characteristics of a highly malignant neoplasm [37–39]. We report that V-ATPase 
inhibition causes F-actin cytoskeleton reorganization in PC3. It reduces or eliminates the 
filopodia projecting from the cell surface and provokes accumulation of F-actin ring 
structures. The F-actin rings differ from invadopodia [40], as the rings are depleted of 
vinculin. In addition, vesicle trafficking, cell invasion, and migration that are invadopodia 
associated processes stall. While there is evidence that normal arrangement of 
filamentous actin is disrupted if V-ATPase is defective [41–43], V-ATPase dependent F-
actin ring assemblies have not been previously reported in cancer or other higher 
eukaryotic cell. Thus, particular F-actin reorganization driven by V-ATPase inhibition may 
be cancer and cell type specific. 
4.3. Materials and Methods 
Cell culture. PC-3 cells were cultured in RPMI-1640 media (Gibco, Grand Island, NY) 
supplemented with 10% Fetal Bovine Serum (SIGMA, St. Louis, MO).  All experiments 
were performed with cells less than 50 passage and with three biologically independent 
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experiments unless otherwise stated. PC-3 cells were authenticated using short tandem 
repeat profiling and were free of mycoplasma contamination. 
Quantitative real-time PCR (qRT-PCR). RNA was isolated using the RNeasy Mini kit 
(Qiagen, Germantown, MD, USA) and reverse transcribed with the RETROscript® cDNA 
kit (Applied Biosystems, Foster City, CA, USA). Primers (Table 1) were designed using the 
PrimerQuest tool from Integrated DNA Technology.  qRT-PCR was performed with SYBR 
Green I Mastermix (Roche, Indianapolis, IN, USA) on a Roche LightCycler 480 II.  Analysis 
was performed using Ct method and expression of β-glucuronidase (GUSB) was 
used to normalize for variances in cDNA input [73]. Samples were analyzed in four 
independent experiments. 
Table 1.- Primers used for qRT-PCR 
Protein Forward Primer 5′- 3′ Reverse Primer, 5′- 3′ 
GUSB CTCATTTGGAATTTTGCCGATT CCGAGTGAAGATCCCCTTTTTA 
V1A GCCCATTCTACAAGACAGTAGG CTCCCATGTGCTCACGAATAA 
Voa1 CACTGGGTTGAGTTCCAGAATA TCACTCTTCAAACTTCCCTTCC 
Voa2 TCTGTCCCTGTCCTCTTCTT CCTTATAAGTGTGTAGCCACTCC 
Voa3 ATGACCTTCCTCATCTCCTACT GCTGCAGAAACGGGAAGA 
Voa4 TGATTTCTGTGCCGTGGATG TGTTCTCAGTGGCATCTTCTTG 
 
Cell viability assay. Cell viability was assessed with Tetrazolium MTT (3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) Assays (ATCC, Manassas, VA). 
The cells were exposed to two different V-ATPase inhibitors, bafilomycin A (BAA) (VWR, 
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Radnor, PA) or concanamycin A (CCA) (Wako, Japan), at the indicated doses and times. 
Acridine Orange staining. To assess changes in pH of acidic vesicles, cells were 
incubated with acridine orange (SIGMA, St. Louis, MO, USA; 1 µM in media) for 30 
minutes at 37oC, then fixed on glass slides with 4% paraformaldehyde. Slides were 
imaged with META/AxioObserver (Thornwood, NY, USA).   
Endosome/Lysosome pH measurements. Cells were incubated with 1 mM 8-
Hydroxypyrene-1,3,6-trisulfonic acid (HPTS) (Life Technologies, Carlsbad, CA, USA) for 16 
hours, then treated with vehicle (0.005% DMSO), 5 nM CCA (Wako, Japan), or 50 µM 
chloroquine (SIGMA, St. Louis, MO, USA) for 1 hour. Fluorescence was measured using a 
FluoroMax 4 spectrofluorometer (Horiba Jobin Yvon, Irvine, CA, USA) with an excitation 
ratio of 458/405 nm at a fixed emission of 515 nm. The HPTS fluorescence excitation 
458/405 ratio was determined and converted to pH values by comparison to standard 
curves generated using known pH buffers (i.e., pH 5 to pH 8) using a non- 
lineal regression.  
Immunocytochemistry. Immunocytochemistry was performed at room temperature 
following standard procedures [16]. Line profiles of fluorescent intensity were obtained 
using ZEN 2009 Light Edition © Carl Zeiss MicroImaging software. Pearson’s correlation 
r values were used to characterize the degree of overlap between fluorescent channels, 
using SlideBook 5.0 software. The V-ATPase subunit V1A antibody was generated by 
BioGenes (Berlin, Germany) and validated  [16]. The antibodies to LAMP1 (lysosome 
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marker, ab25630), giantin (Golgi marker, ab37266) and clathrin (vesicle marker, ab2731) 
were purchased from Abcam (Cambridge, UK). The antibody to transferrin receptor 
(endocytic vesicle marker, 136800), the antibody for AlexaFluor488-phalloidin, and the 
secondary antibodies AlexaFluor488 (A-11001) and AlexaFluor546 (A-11010) were 
purchased from Invitrogen (Grand Island, NY, USA).  
Motility and invasion assays.  In vitro motility and invasion assays were performed 
following manufacturer’s protocols (BD Biosciences, San Jose, CA, USA) in 24-well plates 
containing 2.5 x 104 cells plated on control or matrigel-coated inserts. Cells were treated 
with BAA or CCA, 5 nM, or vehicle (0.005% DMSO) for 24 hours. Fetal Bovine Serum 
(10%) was used as the chemoattractant. Invaded cells were fixed and stained and then 
counted using a microscope (10X, ZEISS Axiovert 25).  
Western blot. RIPA buffer was utilized to prepare whole cell lysates using standard 
procedures. Protein concentrations of whole cell lysates were determined using BCA 
assay (Pierce). 100 µg protein of whole cell lysates were diluted in 4X Laemmli Buffer 
prior to loading on 8% polyacrylamide gels.  Primary antibodies against V1A (Michel et 
al 2013) and β-actin (SIGMA) were diluted in 5% milk in TBS-T 1:1000.  Immunoblots 
were imaged using the ChemiDocTM XRS workstation (BioRad).   
Wound healing assay. A confluent monolayer of cells was “scratched” with a 200 µl 
pipette tip to create a “wound” to induce motility in the absence (0.005% DMSO) or 
presence of BAA or CCA, 5 nM. Scratch width (µm) was imaged every 2 hours using a 
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20x objective. For analysis, scratch width (µm) was determined using AxioVision LE (Carl 
Zeiss Microscopy) software. Scratch width was compared between conditions at each 
time point. 
Statistical analysis. Mann-Whitney tests were performed to determine statistical 
significance between groups using GraphPad Prism 5 software (San Diego, CA, USA). A p 
< 0.05 was considered statistically significant. 
 
4.4. Results 
Inhibition of pH regulation has been proposed as a therapeutic strategy in cancer 
cells [44], because V-ATPase is involved in metastasis and is exploited by tumors to 
survive, proliferate, and resist therapy [45]. Development of chemotherapeutic V-ATPase 
inhibitors requires understanding the complexity of cellular processes deregulated upon 
V-ATPase inhibition. These processes remain mainly elusive. We studied the downstream 
physiological consequences of inhibiting V-ATPase in the prostate carcinoma cells PC-3, 
from V-ATPase distribution, invasion, and migration to its effects on the organization of 
F-actin.  
PC-3 cells predominantly express V-ATPase Voa2 and Voa3 subunit isoforms.     
Human cells express four isoforms of the V-ATPase Vo subunit a (Voa1, Voa2, Voa3, and 
Voa4) [7,10] that target V-ATPase to different cellular membranes [7,10,46]. To determine 
the Vo subunit-a isoform preferentially expressed in PC-3 cells, we used qRT-PCR to 
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measure relative expression of these four Voa isoforms. The subunit V1A is assembled in 
every V-ATPase complex, regardless of the membrane and cell type. Thus, the subunit 
V1A was monitored as a means of detecting all V-ATPase complexes in PC-3 cells. PC-3 
cells expressed comparable amounts of Voa2 and Voa3 but did not have detectable 
levels of Voa1 and Voa4 (Figure 1A). These results suggest that V-ATPase complexes 
containing the Voa2 and Voa3 isoforms are predominant in PC-3 cells.  
V-ATPase is distributed in the Golgi compartment, endosomes and 
lysosomes.  To analyze the cellular distribution of V-ATPase pumps in PC-3 cells, we 
used immunofluorescence confocal microscopy, using antibodies against the V-ATPase 
subunit V1A [16] and markers for various compartments of the endomembrane system. 
As anticipated, V-ATPase was present in the Golgi compartment (giantin), clathrin-
coated vesicles (clathrin), lysosomes (LAMP1), and recycling endosomes (transferrin 
receptor, TfR) (Figure 1B). However, the Pearson’s correlation was greater for giantin and 
clathrin, indicating that there was a higher degree of co-localization (~2-fold) of V1A 
with giantin and clathrin (Pearson r  = 0.46 ± 0.02 and r  = 0.38 ± 0.02, respectively) than 
LAMP1 and TfR (Pearson r  = 0.20 ± 0.03 and r  = 0.21 ± 0.02, respectively, Figure 1C). 
Thus, in PC-3 cells, V-ATPases are primarily located in the Golgi compartment and 
clathrin-coated vesicles with fewer detectable V-ATPases in the lysosomes and recycling 
endosomes.  
V-ATPase inhibitors disturb organelle acidification and endomembrane 
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trafficking.  Its prominent co-localization with giantin suggests that V-ATPase plays 
important roles in membrane trafficking from the Golgi compartment. We treated PC-3 
cells with the plecomacrolide antibiotics bafilomycin A (BAA) and concanamycin A (CCA), 
two highly potent and specific V-ATPase inhibitors that bind to the proteolipid subunit c 
in the Vo domain, which is directly involved in proton transport [47–49]. These inhibitors 
are frequently used to study V-ATPase in a variety of cell types [49]. However, prolonged 
exposure to these plecomacrolides can result in cell death  [48].  Therefore, we first 
assessed PC-3 cell viability. We measured metabolic activity as the reduction of 
Tetrazolium MTT by NAD(P)H-dependent oxidoreductases in viable PC-3 cells exposed 
to 0.01-1000 µM BAA or CCA at 24, 48, and 72 hours. The V-ATPase inhibitors BAA and 
CCA reduced cell viability in a dose- and time-dependent manner (Figure 2). The fraction 
of living cells relative to control untreated cells decreased upon exposure to 
concentrations above 10 nM for the 48 and 72 hour treatments, but not at 24 hours. 
Although 5 nM concentrations of BAA and CCA did not significantly decrease cell 
viability at 24 and 48 hours (Figure 2), V-ATPase function was inhibited. Intracellular 
organelle acidification was disrupted upon treatment with BAA and CCA (Figure 3A), as 
measured by decreased accumulation of the weak lipophilic base acridine orange 
relative to control cells exposed to vehicle alone (DMSO). To quantify these 
observations, we measured the luminal pH of endosomes and lysosomes 
fluorometrically using the pH-sensitive fluorescent dye HPTS, which is trapped in acidic 
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compartments via endocytosis [50]. For these studies, PC-3 cells were exposed to the V-
ATPase inhibitors for 1 hour, because prolonged exposure blocks endocytosis [10]. 
Treatment with 5 nM CCA (Figure 3B) increased the pH of endosomes and lysosomes 
from pH 6.7 to pH 7.1 (p = 0.02). Chloroquine (50 µM), which alkalinizes these 
intracellular compartments independent of V-ATPase pumps, raised the pH to 7.3. We 
concluded that V-ATPase proton transport was effectively blocked in the PC-3 cells 
exposed to V-ATPase inhibitors at concentrations as low as 5 nM. 
Loss of pH gradients upon V-ATPase inhibition impairs membrane turnover and 
endocytic processes [51]. Accordingly, BAA and CCA treatments increased the number 
and size of intracellular vesicles detected by phase contrast (Figure 3C), which were 
further examined by confocal microscopy. Immunocytochemistry showed increased 
signals for clathrin (clathrin-coated vesicles), LAMP1 (lysosomes), transferrin receptor 
(recycling endosomes), and giantin (Golgi) following V-ATPase inhibition (Figure 4). The 
lysosomes, clathrin-coated vesicles, and recycling endosomes were visualized larger and 
more numerous after 48 hours, as the respective markers (LAMP1, clathrin, and 
transferrin receptor) were increased after CCA exposure as compared to control (Figure 
4B). Pearson’s r values increased 5-7-fold in recycling endosomes, indicating that V-
ATPase was retained in these compartments. In contrast, a modest decrease relative to 
controls was measured for LAMP-1 and clathrin positive membranes at 48 hours. 
Moreover, the level of Golgi-associated V-ATPase increased, as shown by its co-
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localization with giantin. Significantly greater Pearson’s r values in the Golgi at 48 h 
(Figure 5A) indicate that vesicle trafficking from the Golgi compartment was also 
blocked. V-ATPase expression did not change, as the total level of V1A subunit detected 
in whole cell lysates by Western blots was not different in PC3 cells after treatment with 
BAA and CCA (Figure 5B). Western blots showed that V-ATPase was stable, indicating 
that these Pearson’s r value variations reflect vesicle traffic alterations. Together, these 
results indicate that active V-ATPase function is required for distribution of V-ATPase to 
different cell membranes and endocytic trafficking via plasma membrane recycling 
pathways in the PC-3 cells.  
V-ATPase inhibition impairs in vitro motility and invasion. The resemblance of 
PC-3 to advanced PCa tumors cells with high metastatic potential is illustrated by the 
high motility and invasive phenotype of the cells [38,39,50,51]. These phenotypes were 
very sensitive to V-ATPase inhibition. Treatment with V-ATPase inhibitors significantly 
decreased in vitro invasion and motility by about 50% or more (Figure 6A, 6B). 
Independent measurements using a wound-healing assay also showed V-ATPase-
dependent inhibition of cell motility. When a confluent monolayer of cells treated with 
CCA was “wounded” by scratching, the cells exhibited significant delay to close the 
wound width relative to vehicle treated cells (DMSO). It took 1.6-fold longer for CCA 
treated cells to close the wound (23 hours) than untreated cells (14 hours) (Figure 6 C,D). 
Thus, PCa V-ATPase is crucial in the invasive disease and inhibition of its activity reduces 
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PC-3 cell motility.  
Directed cell motility provokes redistribution of V-ATPase containing 
vesicles. In several tumor cell lines, including PC-3, plasmalemmal V-ATPase extracellular 
acidification was shown to contribute to in vitro invasion and motility [7,9,15,16,18]. We 
did not find detectable levels of V-ATPase at the plasma membrane of PC-3 cells using 
the anti-V1A antibody (Figure 1B, Figure 4), even though this antibody recognizes all V-
ATPase pumps in a cell. We asked whether trafficking of V-ATPase to the plasma 
membrane is inducible, particularly if cell motility can cause V-ATPase transfer to the 
plasma membrane in PCa cells, as shown in breast cancer cells [52]. Confluent 
monolayers of PC-3 cells were “wounded” by introducing a scratch. The cells were fixed 
(4 hours post scratch) and V-ATPase cellular localization visualized in the cells farthest 
from the wound (non-migrating cells in Figure 7) and the cells that have crawled to the 
middle of the wound (migrating cells in Figure 7). Actin cytoskeleton provides cells with 
mechanical support for vesicle and cell movement. We monitored F-actin with phalloidin 
and asked whether V-ATPase co-localized with F-actin. V-ATPase co-localized with F-
actin in vesicles near the leading edge of the migrating cells, but not in the non-
migrating cells. These results indicated that directed movement to the scratch provoked 
redistribution of V-ATPase containing vesicles and their co-localization with actin 
filaments toward the leading edge, to the front of migrating cells.  
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V-ATPase inhibition prompts F-actin reorganization. We visualized F-actin 
with phalloidin after V-ATPase inhibition because actin remodeling is pH-dependent 
[53] and plays important roles in cancer cell motility and invasion. F-actin bundle 
filopodial extensions were significantly reduced. The CCA treated cells exhibited short 
filopodia-like protrusions as compared to untreated cells (arrow heads, Figure 8A).  In 
addition, F-actin formed ring structures of different sizes after treatment with CCA 
(arrows, Figure 8A). The number of cells containing F-actin rings increased from 2% prior 
to CCA treatment to 66.3 ± 8% after 24 hours and 77.5 ± 10.5% after 48 hours of CCA 
exposure (Figure 8B).  Smaller rings also were visible at 48 hours. F-actin rings were also 
observed after treating the cells with chloroquine, which alkalinizes organelles 
independently of V-ATPase activity. The number of chloroquine treated cells presenting 
F-actin rings was nearly the same at both times, 24 and 48 hours, although the smaller 
rings were remarkably more abundant 48 hours post-treatment than 24 hours. 
Comparisons between chloroquine and CCA treated cells revealed a larger amount of 
small F-actin rings with chloroquine. These results indicate that disruption of organelle 
luminal acidic pH and membrane pH gradients with either V-ATPase inhibitors or 
chloroquine caused F-actin reorganization into rings.  
The F-actin rings resembled invadosomes [54] described at the matrix focal 
degradation area in invasive cancer cells, including PC-3 cells [55]. However, the 
adhesion plaque protein vinculin and the protein tyrosine kinase Src substrate Tks5, 
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which are linked for the formation and function of invadosomes did not co-localize with 
the rings by immunocytochemistry (Supplemental figure 1). Organelle acidification is 
also necessary for MMPs transport to the invadosomes and extracellular matrix 
degradation [18,34] . However, endo-lysosomal acidification was impaired by V-ATPase 
inhibitors and chloroquine treatment (Figure 3C), suggesting that these F-actin rings 
were not functional invadopodia or podosomes. Similar F-actin ring structures assemble 
on Dictyostelium discoideum lysosomes to promote exocytosis of indigestible material 
[56]. We examined the lysosomal markers LAMP1 and LAMP2 to determine whether the 
F-actin rings resulted from during lysosomal V-ATPase retrieval/recycling [56]. LAMP1 
and LAMP2 were not detected (Supplemental figure 2).  
4.5. Discussion 
A repertoire of studies have shown that V-ATPase pumps play essential roles in 
carcinogenesis [9,14–19,24–27]. V-ATPase proton transport and its central roles in pH 
homeostasis contribute to several important cellular processes and cancer phenotypes, 
including invasion and metastasis [9,14–19,24–27].  However, the scope of cellular 
responses driven by V-ATPase inhibition is complex and remains largely elusive in 
cancer cells.  
V-ATPase is highly abundant in clathrin containing cytosolic vesicles (Figure 1), 
consistent with its crucial role in receptor-mediated endocytosis by controlling the 
intralumenal pH of vesicles. In the PC-3 cells, V-ATPase inhibition leads to the 
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accumulation of internalized clathrin-coated vesicles (Figure 4), indicating that the 
internalized membranes are trafficked into endosomes, but cannot be sorted back to 
the surface of the cell or into other compartments (lysosomes) for cargo degradation. 
Endocytosis controls constitutive and stimulated nutrients uptake and internalization of 
many receptors with roles in cellular homeostasis, growth control, and cell 
differentiation. Clearly, V-ATPase inhibition leads to widespread vesicle trafficking 
defects that contribute to hindering PC-3 cells invasive phenotypes (Figure 6).   
A large number of cytosolic vesicles accumulated in cells treated with the V-
ATPase inhibitors (Figures 3B and 4), which is testimony to the central role that V-ATPase 
proton transport has in endocytic and exocytic traffic. A substantial increase of Pearson’s 
values in the trans-Golgi network (giantin) and recycling endosome (transferrin 
receptor), but not in lysosomes (LAMP-1) after V-ATPase inhibition (Figure 5) is strong 
evidence of defective clathrin-independent endocytosis recycling pathway. The recycling 
pathway of post-internalized vesicles consists of three main routes for cargo sorting out 
from the early endosome: retrograde traffic (to the trans-Golgi network and back to the 
plasma membrane), slow traffic (to the recycling endosome and recycled back to the 
plasma membrane), and rapid traffic (directly back to the plasma membrane) [57]. This 
study suggests that V-ATPase’s foremost contribution is to the retrograde and slow 
traffic rather than the degradation pathway, which runs from the early endosome to the 
lysosome, delivering cargo that needs to be degraded. This study also suggests that 
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retrograde and slow traffic are major recycling routes in the PC-3 PCa cells and that V-
ATPase activity is crucial to deliver vesicles from the Golgi and recycling endosomes to 
the plasma membrane. 
In addition to impairing fundamental V-ATPase functions such as endo-lysosomal 
lumen acidification and vesicle trafficking, cell migration is severely inhibited and 
important F-actin cytoskeleton rearrangements occur when V-ATPase is not active. One 
change is the reduction of filopodial projections that are known to facilitate motility; 
interestingly, these projections require intracellular trafficking. Cell migration requires F-
actin assembly into thin, fingerlike extensions called filopodium that are necessary for 
motility [14,16,17,52]. Reduction or elimination of filopodia (Figure 8, arrowheads) after 
treatment with CCA indicates that V-ATPase inhibition reduces the migration velocity of 
the PC-3 cells by disturbing filopodium assembly (Figure 6). Consequently, V-ATPase 
offers a therapeutic target for disturbing the integrity of the actin cytoskeleton and 
prostate cancer progression.   
There are multiple actin-based functions known during exocytosis [58,59]. Actin 
rings associated with vesicle membranes provide a stronger force to overcome stressing 
environmental factors in the exocytosis of large granules (Nightingale et al., 2012). In the 
PC-3 cells, the amount of cytoplasmic F-actin rings formed after treatment with sub-
lethal concentrations of V-ATPase inhibitors increases from 24 to 48 hours (Figure 8B), 
suggesting that these F-actin ring structures might be a stress response to alleviate 
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traffic defects. One possibility is that the F-actin rings directly localize on the surface of 
these vesicles to facilitate exocytosis of material trapped with congested endosomes, 
similar to the F-actin coats and rings on exocytic organelles which promote regulated 
exocytosis in acinar cells [59].  
After inactivating V-ATPase pumps, F-actin rings may assemble to enable actin-
based force exocytosis to reduce exaggerated accumulation of vesicles and downstream 
deleterious effect. We detected similar ring arrangements using anti-transferrin receptor 
antibodies in PC-3 cells treated with CCA (Figure 4A, arrows). This observation is in line 
with the idea that F-actin rings may have assembled on these endosomal membranes. 
Our data suggests that V-ATPase inhibitors impair traffic of internalized membrane 
vesicles back to the plasma membrane. We propose that F-actin rings formed in 
response to V-ATPase inhibition might act at that stage of late endosomal recycling, as 
suggested for WASH–F-actin patches in Drosophila  [60], even though Drosophila F-
actin ring structures differ from the F-actin rings in PC-3 cells, as they retain the lumen 
acidic pH in Drosophila. Notably, in D. discoideum, V-ATPase inhibition or treatment 
with chloroquine induce assembly of F-actin into rings on the surface of large lysosomes 
to promote exocytosis of indigestible material [56]. However, F-actin co-localization with 
the LAMP1 and LAMP2 lysosomal markers is negligible in PC-3, indicating that assembly 
of F-actin rings in the PC-3 cells is a distinctive pro-survival response to alleviate traffic 
defects upon V-ATPase inhibition.  
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V-ATPase is directly involved in interactions with the actin cytoskeleton [41,61–63]. Actin 
organization defects resulting from V-ATPase inhibition have been shown in yeast 
[43,64], insects [62,65], and HeLa cells [42]. In the PC-3 cells, this study shows that 
proximity of V-ATPase to F-actin is inducible and stimulated by polarized cell migration 
(Figure 7). V-ATPase co-localizes with F-actin only in vesicles neighboring the leading 
edge, not at the plasma membrane as reported in breast cancer cells [52]. Thus, spatial-
temporal interactions between F-actin and V-ATPase could be cancer and cell type 
specific. In fact, V-ATPase does not co-colocalize with actin in the Golgi of PC-3 cells, as 
reported before in HeLa cells [66].  
Plasma membrane V-ATPase has been shown to generate a low extracellular pH 
that is important for the activation of proteases that degrade the extracellular matrix, 
thereby allowing for metastasis in aggressive cancer cell lines  [7,9,19,67,68]. V-ATPase 
subunit V1A was negligible on the plasma membrane by immunocytochemistry analyses, 
despite the fact that: 1) V-ATPase dependent proton efflux and extracellular acidification 
have been measured in the PC-3 cells [18]; and 2) PC-3 displays highly invasive and 
androgen-insensitive phenotypes and the cell line PC-3 is considered a good cell model 
of ablation resistant prostate cancer [37–39] and prostatic small cell carcinoma [69,70]. 
One explanation is that changes in the cytoplasm drive downstream extracellular 
changes when V-ATPase is not functional. Since V-ATPase is remarkably more abundant 
intracellularly than on the cell surface, it is likely that the intracellular pumps are largely 
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responsible for the in vitro invasion and cell migration defects induced with BAA and 
CCA in PC-3 cells.  
V-ATPase complexes containing the Voa2 and Voa3 subunit isoforms appear to 
have essential roles in PC-3 cell invasiveness and motility, intracellular membrane 
trafficking, and V-ATPase dependent F-actin reorganization into rings (Figure 1A).  
Subunit Voa3 is expressed on the plasma membrane of invasive breast cancer cells, 
pancreatic cells, melanoma cells, and ovarian cancer tissue and has been linked to 
enhanced tumor cell invasion [52]. Plasma membrane V-ATPase containing the Voa1 
subunit isoform was shown to contribute to cell invasion in PC-3 [18]. However, the Voa1 
subunit isoform was not measurable in our studies, and V-ATPase was not detected on 
the plasma membrane.  Our results are consistent with previous report that Voa1 
transcripts are absent in the PC-3 cells [71]. One explanation to these disparate results is 
that Voa1 expression is inducible. These results may be a consequence of the different 
growth conditions or methods used to assess Voa isoforms (SNP arrays, microarray, qRT-
PCR, and western blots). Nonetheless, it remains a challenge to establish how V-ATPase 
subunit isoforms contribute to specific tumorigenic phenotypes, because subunit 
isoforms can functionally compensate for each other [8] and the V-ATPase inhibitors 
available do not discriminate between isoforms. 
In summary, the PC-3 cells treated with V-ATPase inhibitors display important F-
actin reorganizations, including reduction of filopodial arrangements that blocks 
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migration. The finding that PC-3 cancer cells accumulate intracellular F-actin rings that 
resemble exocytic F-actin rings in response to organelle pH alterations is novel. V-
ATPase-dependent F-actin ring formation has not been described in prostate or any 
other cancer cell type. Actin is the most abundant protein within a cell and is responsible 
for cellular movement within the microenvironment. Actin is also linked to the cellular 
mechanism by which cells dissociate with their microenvironment and become 
metastatic. Pharmacological inhibition of V-ATPase may offer a therapeutic platform for 
targeting the integrity of the actin cytoskeleton to impair cancer progression [72]. An 
interesting hypothesis is that F-actin rings assemble on the surface of these organelle 
membranes to promote their traffic and/or release their content, as a means of 
overcoming a widespread vesicle traffic jam caused by organelle pH alterations upon V-
ATPase inhibition. Future studies will determine the specific function of these F-actin 
rings and whether they provide actin-based force to promote exocytosis and reduce 
toxic accumulation of vesicles and their cargo upon V-ATPase inhibition in PCa cells and 
other cancers. 
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4.6. Figures 
 
Figure 1. V-ATPase expression and distribution in PC-3 cells. A. V-ATPase subunits 
(V1A, Voa1, Voa2, Voa3 and Voa4) mRNA was quantified by qRT-PCR and normalized to β-
glucuronidase (GUSB) in PC-3 cells. Data are expressed as mean ± SE  B. The cells were 
immunostained with antibodies against the V-ATPase subunit V1A and markers of the 
Golgi compartment (giantin), clathrin-coated vesicles (clathrin), lysosomes (LAMP1) and 
recycling endosomes (transferrin receptor, TfR). Co-localization was analyzed using 
confocal microscopy determining a line profile of fluorescence intensity. Arrow = line 
profile x axis.  Scale bar = 10 µm. C. Pearson r values were obtained to characterize the 
degree of overlap between V1A signal and either giantin, clathrin, LAMP1 or transferrin 
receptor (TfR). Data (r values) are expressed as mean ± SE.  n= 50 cells. 
 
 
 
 
 
114 
 
 
 
 
Figure 2. V-ATPase inhibition diminishes PC-3 cell survival in a dose dependent 
manner.  MTT viability of PC-3 cells treated for 24, 48, and 72 hours with the indicated 
concentrations of BAA or CCA.  Data are expressed as live fraction relative to vehicle-
treated control (mean ± SE; n = 3).  
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Figure 3. V-ATPase inhibition disturbs organelle acidification and triggers 
intracellular vesicles accumulation in PC-3 cells. A. PC-3 cells were treated with 
0.005% DMSO (control), BAA (5 nM) or CCA (5 nM) for 24 hours (top panel) and 48 
hours (bottom panel). Intracellular pH was qualitatively assed using the pH-sensitive dye 
Acridine Orange.  Acridine Orange accumulates in acidic vesicles and, at low pH, emits 
fluorescence. Cells were stained with 1 µM acridine orange (green) for 30 minutes and 
analyzed using fluorescent confocal microscopy. DAPI (blue) was used as nuclear marker. 
The decrease or loss of green fluorescence indicates alteration in organelle acidification. 
Scale bar = 20 µm.  B. PC-3 cells were incubated with the pH- sensitive fluorescent dye 
HPTS for 24 hours and then treated with DMSO 0.005% (control), 5 nM CCA, or 50 µM of 
chloroquine (ChQ) for 1 hour.  Cells were collected, washed and analyzed using a 
fluorometer.  Endo- Lysosome pH was determined by comparing the fluorescence with 
an excitation ratio of 458/405 nm at a fixed emission of 515 nm to a standard curve 
generated using known pH buffers. Mean endosome and lysosome pH is shown ± SE 
from 3-5 experiments. C.  Phase contrast images of PC-3 cells treated with vehicle 
control (DMSO 0.005% in media), 5 nM BAA, or 5 nM CCA for 24 hours (top panel) and 
48 hours (bottom panel). Arrows indicate vesicle accumulation. Images were obtained 
with a Primo Vert microscope. Scale bar = 20 µm.   
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Figure 4. V-ATPase inhibition leads to accumulation of lysosomes, clathrin-coated 
vesicles and recycling endosomes.  A. PC-3 cells were fixed after 24 hour incubation 
with vehicle control media (DMSO 0.005% in media) (top panel) or with 5 nM of the V-
ATPase inhibitor (+ CCA, botton panel) then co-immunostained with antibodies against 
the V-ATPase subunit V1A (red) and the indicated marker proteins (green). After 
treatment, vesicular accumulation of lysosomal composition was observed. White 
arrows: ring structures positive for TfR. B. PC-3 cells were fixed after 48 hour incubation 
with conditions described above. After treatment, vesicular accumulation of lysosomal 
and endosomal composition was observed. Scale bars = 10 µm. 
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Figure 5. Pearson analyses show V1A subunit accumulation in Golgi and 
endosomes. A. Pearson r values were obtained to characterize the degree of overlap 
between V1A signal and either giantin (Golgi), clathrin (clathrin-coated vesicles), LAMP1 
(lysosomes) or transferrin receptor (endosomes, TfR). Confocal microscopy images were 
analyzed. Data are expresed as Pearson r score relative to control matched to 1. n = 50 
cells. B. Pearson r values were obtained as described for Figure 5A, both in control 
conditions and after 48 hour incubation with 5 nM BAA and CCA. Data are expresed as 
Pearson r relative to control matched to 1. n = 50 cells analyzed. C. PC-3 whole cell 
lysates were obtained after 24 or 48 hours incubation with vehicle control media (DMSO 
0.005% in media), 5 nM BAA or 5 nM CCA. Western blots were used to monitor the V-
ATPase subunit V1A (Michel 2013) and β-actin (loading control).  
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Figure 6. PC-3 motility and invasion are impaired by V-ATPase inhibition. A. PC-3 
cells were placed in matrigel-coated inserts (8 µm pores) in the absence (control) or 
presence of V-ATPase inhibitors (BAA or CAA at 5 nM) for 24 hours. Fetal bovine serum 
(10% v/v) was used as chemoattractant; * p < 0.05,  **** p < 0.0001, n= 3 independent 
experiments. B. PC-3 cells were placed in migratory inserts (8 µm pores) in a 24-well 
plate in absence (control) or presence of V-ATPase inhibitors (BAA or CAA 5 nM) for 24 
hours. Fetal bovine serum (10% v/v)  was used as chemoattractant; ** p < 0.01, **** p < 
0.0001, n= 3 independent experiments.  C. PC-3 cells were grown in a confluent 
monolayer and then a scratch was made to create a “wound” and induce motility (time 
0) in absence (DMSO 0.005% in media, top panel) or presence of 5 nM CCA (+CCA, 
bottom panel). Representative pictures at 0, 8, 14, and 20 hours after the scratch were 
taken. Images were obtained with an AxioVision 4.8 microscope. Scale bar = 200 µm. D. 
PC-3 cells were imaged every 2 hours and the scratch width (µm) values were expressed 
as % of width relative to time 0. (mean ± SE)* p < 0.05, ** p < 0.01, *** p < 0.0001. n = 3 
repetitions. Comparable results were obtained after BAA exposure (not shown). 
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Figure 7. V-ATPase is found in vesicles near the leading edge in migrating PC-3 
cells.  PC-3 monolayers in control media were wounded as previously described for 
Figure 6. Cells were fixed after 4h. Representative non-migrating cells farthest from the 
wound (top) and migrating cells that have crawled to the middle of the wound (bottom) 
are shown.  Distribution of V-ATPase subunit V1A (red) and phalloidin (F-actin, green) 
was visualized by confocal microscopy. DAPI (blue) was used as nuclear marker. Scale bar 
= 10 µm. Co-localization was analyzed by determining a line profile of fluorescent 
intensity as described for Figure 1. Scale bar = 10 µm.  
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Figure 8. CCA and ChQ treatment induce accumulation of F-actin rings. A. PC-3 
cells were fixed after 24 hour (top) or 48 hour (bottom), incubated with vehicle control 
media (DMSO 0.005% in media),  5 nM of CCA or 50 µM of ChQ, and immunostained 
with phalloidin (green). DAPI (blue) was used as nuclear marker. White arrows = F-actin 
rings. White arrowheads = filopodial projections. Scale bar = 10 µm. B. F-actin rings 
were measured in several microscope pictures and the percentage of cells with F-actin 
rings counted. n ≥ 37 cells. ** p < 0.01, *** p < 0.001 
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Supplemental Figure 1. CCA-induced F-actin rings does not co-localize with 
vinculin nor Tsk5. PC-3 cells were fixed after 48 hours incubation with vehicle control 
media (DMSO 0.005% in media) and the V-ATPase inhibitor (+ CCA) then co-
immunostained with antibodies against the invadosome markers vinculin (A, red) or Tsk5 
(B, red) and phalloidin (F-actin marker, green). There was no co-localization between 
neither of the markers and the F-actin rings. White arrows = F-actin rings. Scale bars = 
10 µm. 
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Supplemental Figure 2. CCA-induced F-actin rings does not co-localize with LAMP1 
nor LAMP2. PC-3 cells were fixed after 48 hours incubation with vehicle control media 
(DMSO 0.005% in media) and the V-ATPase inhibitor (+ CCA) then co-immunostained 
with antibodies against the lysosome markers LAMP1 (A, red) or LAMP2 (B, red) and 
phalloidin (F-actin marker, green). There was no co-localization between neither of the 
markers and the F-actin rings. White arrows = F-actin rings. Scale bars = 10 µm. 
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 CHAPTER V- DISCUSSION AND FUTURE DIRECTIONS 
Prostate cancer (PCa) is the most commonly diagnosed cancer and the 3rd 
leading cause of death for men in the United States [1]. This report shows that 
fundamental functions of V-ATPase pumps, such as generating and maintaining the 
differential acidic pH across the endo-membrane system, has long reaching effects in 
PCa cells (summarized in Table 5.1).  
Our studies determined a broad spectrum of cellular events that require V-
ATPase regulation of endosomal and lysosomal pH that are important for PCa survival 
such as migration and invasion, vesicular trafficking, PSA secretion and expression, AR 
expression, iron homeostasis, HIF-1α degradation, and F-actin reorganization, 
(summarized in Table 5.1). [2].  
V-ATPase localizes predominantly in the Golgi compartment in PCa cell lines 
(Chapters II-IV), indicating that V-ATPase may play essential roles in sorting of proteins 
to different organelles. The Golgi pH deregulation has been linked to the fragmentation 
in tumors [3] that leads to changes in glycosylation [4], but roles of V-ATPase activity in 
Golgi fragmentation are unknown. Whether high expression of V-ATPase in the Golgi is 
exclusive to tumors and whether it contributes to Golgi fragmentation in PCa is not 
known. It needs to be addressed in future studies.  
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V-ATPase inhibition alkalinizes endosomes and lysosomes in LNCaP, LAPC4 and 
PC-3 cells (Chapter II and IV). Tight control of the pH in the endomembrane system is 
required for membrane trafficking [5,6], thus vesicular trafficking is impaired after V-
ATPase inhibition with CCA. Clathrin (clathrin-coated vesicles), LAMP1/LAMP2 
(lysosomes), transferrin receptor (recycling endosomes), and PSA (secretory vesicles) 
accumulate in the cytoplasm (Chapters II-IV). Processing and sorting of PSA (Chapter III) 
is defective and PSA is not secreted. Secretion of other proteins is likely are altered as 
well [2]. Straud and collaborators (2012) reported that cytotoxicity after V-ATPase 
inhibition can be rescued by iron in tumor cell lines [7]. Iron is essential for cellular 
development and maintenance of multiple physiological processes [8].  In PCa cells, 
aberrant internalization of iron-loaded transferrin by receptor mediated endocytosis is 
of great repercussions (Chapter II, IV) [2,9]. 
 In Chapter II, we show suppression of AR expression as a new downstream 
consequence of reducing iron uptake in the cells treated with CCA. Chapter II links AR 
expression defects to iron-dependent upregulation of HIF-1α. Exogenous iron rescues 
AR expression levels and HIF-1α hydroxylation in cells treated with V-ATPase inhibitors. 
We concluded that CCA treatment indirectly inhibits HIF-1α prolyl hydroxylation that 
increases HIF-1α. Iron is a cofactor in the HIF-1α hydroxylation reaction that targets HIF-
1α for degradation in the proteasome [10]. Although V-ATPase regulation of HIF-1α has 
been reported in other cell type [11–13], its interconnection with AR expression is novel.  
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Notably, AR expression is not inhibited in the androgen-insensitive cell line C4-2B 
(Chapter III), suggesting that androgen activity may be a factor in the signaling pathway 
that represses AR after V-ATPase inhibition. These findings are critically important for 
the treatment of PCa diseases that thrive in androgen depleted environments. It implies 
that V-ATPase may be targeted to treat PCa initially, but it would not be an appropriate 
treatment for patients that have recurrent tumors or metastatic disease. To determine 
whether androgen activity is necessary, future studies need to measure AR levels in V-
ATPase deficient cells using androgen depleted culture media (e.g., containing 5% 
charcoal) before and after addition of 5α-dihydrotestosterone (DHT).  
 Paradoxically, V-ATPase inhibitors are cytotoxic (Chapter III and IV), even though 
they increase HIF-1α levels which are associated with carcinogenesis and poor 
prognosis. HIF-1α stimulates glycolysis, as a pro-survival response [10,14,15]. 
Independent studies in our laboratory indicate that CCA treatments also increase 
expression of glycolytic enzymes in other cell lines (Fordyce et al., manuscript in 
preparation). In addition to blocking HIF-1α turnover, V-ATPase inhibition impairs 
pathways controlling cell proliferation and apoptosis. V-ATPase inhibitors increase 
expression of pro-apoptotic proteins such as p21 [11]. One possibility is that V-ATPase 
inhibitors promote apoptosis through HIF-1α. A deep mechanistic understanding of the 
cytotoxic effects of stabilizing HIF-1α by V-ATPase inhibition will require studying the 
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CCA effects on HIF-1α-regulated proteins that are involved in hypoxic adaptation and 
growth arrest. 
Future studies need to address the effects in Reactive Oxygen Species (ROS) [16] 
and the cellular process affected, including apoptosis, which is also affected by defective 
iron homeostasis. V-ATPase inhibition generates ROS [7,16,17] and several phenotypes 
observed in the PCa cells can be associated to ROS (Table 5.1.). In future studies, 
superoxide sensitive probes (e.g., DHE) can be used and determine if phenotypes are 
reversed using decreasing ROS with antioxidants (e.g., N-acetyl-L-cysteine) [7].  
A number of reports have shown V-ATPase on the plasma membrane of highly 
invasive cancer cells [2,18–21]. In our studies, V-ATPase is detected in plasma membrane 
fractions of an invasive cell line, C4-2B, but it is not present in less invasive cells such as 
LNCaP [2] (Chapter III). In the PC-3 cell line, which is also considered highly invasive, V-
ATPase is not detected at the plasma membrane by immunocytochemistry analyses, 
even though it co-localizes with F-actin [9] (Chapter IV). In PC-3 cells, V-ATPase is 
associated in vesicles near the leading-edge of cells closing a wound (i.e., migrating 
cells), but non-migrating cells do not accumulate V-ATPase rich vesicles near the plasma 
membrane. Thus, V-ATPase localization on or near the plasma membrane is a dynamic 
process induced by migration in PC-3 cells. In other cells, including microvascular 
endothelial cells [22] and the breast cancer cell line MB-231 [19], plasmalemmal V-
ATPase has been reported in the leading edge.  
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In Chapter IV, we report formation of F-actin rings after V-ATPase inhibition or 
chloroquine treatment. This is important because cell migration and invasion needs 
plasma membrane protrusion and retraction that involve F-actin cytoskeleton [23]. 
Defective F-actin organization may contribute to decrease invasion in PC-3 PCa cells 
after inhibiting V-ATPase. However, the nature of the F-actin rings and their cellular 
function remains unknown. It could be linked to alterations in cytosol pH, because 
increased V-ATPase expression in tumor cells was shown to maintain the slightly high 
cytosol pH characteristic of cancer cells (i.e., ≥ pH 7.2) [5,6,23,24].  
These studies illustrated the complexity and importance of V-ATPase functions in 
prostate tumorigenesis (Table 5.1.) that makes this proton pump attractive tools to 
understand PCa biology. Such studies will require new V-ATPase inhibitors and genetic 
inhibition of V-ATPase. The inhibitors that we used, BAA and CCA, inhibit all V-ATPases 
and cannot discriminate between healthy and tumor cells that precludes selective 
treatment of cancer-specific V-ATPase pumps.   
 
 
 
 
138 
 
 
 
Table 5.1. Summary of Findings 
V-ATPase role Findings  Chapter  
Expression  - V-ATPase subunits mRNA levels are higher in 
more invasive cell lines than less invasive ones 
(RPW1-LNCaP-C4-2B). 
 
- PC-3 cells do not have detectable levels the 
subunits Voa1 and Voa4 mRNA. 
  
III 
 
 
 
IV 
Localization - V1A subunit is detected in plasma membrane 
extractions of C4-2B cells. 
 
- V1A subunit is detected near the leading edge of 
PC-3 cells. 
 
- V1A subunit co-localizes with endosomal (i.e., 
transferrin receptor, clathrin), lysosomal (i.e., 
LAMP1, LAMP2) and Golgi (i.e., Giantin) markers in 
LNCaP, C4-2B and PC-3 cells 
 
- V-ATPase is present in PSA loaded vesicles mostly 
in the Golgi compartment.  
 
 
III 
 
 
IV 
 
 
III, IV 
 
 
 
 
III 
 
Cell Motility 
and Invasion 
- V-ATPase inhibition does not affect migration of 
LNCaP and C4-2B cells but does decrease invasion 
in both cell lines (≤ 70%).  
 
- In PC-3 cells, V-ATPase inhibition decreases both 
migration and invasion (~50%) 
-  
III 
 
 
 
IV 
pH 
maintenance 
- V-ATPase inhibition disturbs vesicular acidification 
in LNCaP, C4-2B, LAPC4 and PC-3 cells. 
 
- 1 hour of CCA treatment increases endo-lysosomal 
PH in about 0.5 pH units (from 6.5 to 7.0 in LAPC4; 
from 6.6 to 7.1 in LNCaP; from 6.7 to 7.1 in PC-3). 
 
II, III, IV 
 
 
II, IV 
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Membrane 
Trafficking 
- V-ATPase inhibition decreases PSA secretion in 
LNCaP cells. 
 
- V-ATPase inhibition leads to an accumulation of 
endosomes (positive to transferrin receptor, 
clathrin), secretory vesicles (PSA) and lysosomes 
(positive to LAMP-1, LAMP-2). V1A distribution in 
those vesicles changes after V-ATPase distribution. 
 
- Accumulation of transferrin receptor by V-ATPase 
inhibition potentially disturbs iron homeostasis. 
 
III 
 
 
III, IV 
 
 
 
 
 
II 
Cytoskeleton - V-ATPase inhibition increases the frequency (66% 
24 hours treatment and 77% 48 hours treatment) 
of F-actin organization (F-actin rings). 
  
IV 
Cytotoxicity 
 
- V-ATPase inhibitors are cytotoxic in a dose- and 
time- dependent manner. PCa cells that are more 
invasive (i.e., PC-3) are more sensitive than cells 
that are less invasive (i.e., LNCaP). 
-   
II, III 
Signal 
Transduction 
 
 
 
 
 
- V-ATPase inhibition decreases PSA mRNA 
expression in LNCaP but not C4-2B cells. 
 
- V-ATPase inhibition decreases AR mRNA 
expression in LNCaP and LAPC4 cells. 
 
- V-ATPase inhibition increases HIF-1α protein levels 
potentially increasing HIF-1 activity. 
 
III 
 
 
II 
 
 
II 
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CHAPTER VI. APPENDIX. 
6.1. Promoter Analysis of Androgen Receptor 
Androgen Receptor promoter analysis (gene name: NR3C4, organism: Homo sapiens ) 
was performed using the Transcriptional Regulatory Element Database [1] (available in 
https://cb.utdallas.edu/cgi-bin/TRED/tred.cgi?process=home). The analysis retrieved two 
promoter sequences (see below): 
Sequence 1: 
>AR:chrX:64997087 [-700..299](+) [human, Homo sapiens] 
gtttttagtgtttgtgtgtttacctgcttgtctgggtgattttgcctttg 
agagtctggatgagaaatgcatggttaaaggcaattccagacaggaagaa 
aggcagagaagagggtagaaatgacctctgattcttggggctgagggttc 
ctagagcaaatggcacaatgccacgaggcccgatctatccctatgacgga 
atctaaggtttcagcaagtatctgctggcttggtcatggcttgctcctca 
gtttgtaggagactctcccactctcccatctgcgcgctcttatcagtcct 
gaaaagaacccctggcagccaggagcaggtattcctatcgtccttttcct 
ccctccctcgcctccaccctgttggttttttagattgggctttggaacca 
aatttggtgagtgctggcctccaggaaatctggagccctggcgcctaaac 
cttggtttaggaaagcaggagctattcaggaagcaggggtcctccagggc 
tagagctagcctctcctgccctcgcccacgctgcgccagcacttgtttct 
ccaaagccactaggcaggcgttagcgcgcggtgaggggaggggagaaaag 
gaaaggggaggggagggaaaaggaggtgggaaggcaaggaggccggcccg 
gtgggggcgggacccgactcgcaaactgttgcatttgctctccacctccc 
agcgccccctccgagatcccggggagccagcttgctgggagagcgggacg 
gtccggagcaagcccagaggcagaggaggcgacagagggaaaaagggccg 
agctagccgctccagtgctgtacaggagccgaagggacgcaccacgccag 
ccccagcccggctccagcgacagccaacgcctcttgcagcgcggcggctt 
cgaagccgccgcccggagctgccctttcctcttcggtgaagtttttaaaa 
gctgctaaagactcggaggaagcaaggaaagtgcctggtaggactgacgg 
 
Sequence 2: 
>AR:chrX:64997098 [-700..299](+) [human, Homo sapiens] 
ttgtgtgtttacctgcttgtctgggtgattttgcctttgagagtctggat 
gagaaatgcatggttaaaggcaattccagacaggaagaaaggcagagaag 
agggtagaaatgacctctgattcttggggctgagggttcctagagcaaat 
ggcacaatgccacgaggcccgatctatccctatgacggaatctaaggttt 
cagcaagtatctgctggcttggtcatggcttgctcctcagtttgtaggag 
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actctcccactctcccatctgcgcgctcttatcagtcctgaaaagaaccc 
ctggcagccaggagcaggtattcctatcgtccttttcctccctccctcgc 
ctccaccctgttggttttttagattgggctttggaaccaaatttggtgag 
tgctggcctccaggaaatctggagccctggcgcctaaaccttggtttagg 
aaagcaggagctattcaggaagcaggggtcctccagggctagagctagcc 
tctcctgccctcgcccacgctgcgccagcacttgtttctccaaagccact 
aggcaggcgttagcgcgcggtgaggggaggggagaaaaggaaaggggagg 
ggagggaaaaggaggtgggaaggcaaggaggccggcccggtgggggcggg 
acccgactcgcaaactgttgcatttgctctccacctcccagcgccccctc 
cgagatcccggggagccagcttgctgggagagcgggacggtccggagcaa 
gcccagaggcagaggaggcgacagagggaaaaagggccgagctagccgct 
ccagtgctgtacaggagccgaagggacgcaccacgccagccccagcccgg 
ctccagcgacagccaacgcctcttgcagcgcggcggcttcgaagccgccg 
cccggagctgccctttcctcttcggtgaagtttttaaaagctgctaaaga 
ctcggaggaagcaaggaaagtgcctggtaggactgacggctgcctttgtc 
 
To analyze this sequences, we used the program TRANSFAC®[2] (manual available in: 
https://portal.biobase-
international.com/build_t/idb/1.0/html/bkldoc/index.html?page=/build_t/idb/1.0/html/b
kldoc/source/bkl/tools/match/match_search.html&label=match_top ) using the predict 
transcription factor binding sites tool. Both sequences retrieved the same transcription 
factors (see table below). Highlighted is the transcription factor AhR (aryl hydrocarbon 
receptor), ARNT (aryl hydrocarbon receptor nuclear translocator also known as HIF-1β).  
 
factor name  Sequence 
FOXJ1 tttgtgTGTTTacctg 
MEQ tTGTGTgtt 
HNF3-beta ttgtgtgTTTACctgct 
FOXA2 ttgtgtgTTTACctgct 
Freac-3 tgtgtgTTTACctgct 
Freac-2 tgtgtGTTTAcctgct 
HNF3A gTGTTTacct 
FOXI1 tgTTTAC 
Foxk1 TGTTTac 
Foxg1 TGTTTac 
FOXP3 TGTTTac 
FOXO6 TGTTTac 
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FOXL1 TGTTTac 
FOXD2 TGTTTac 
FOXO3 TGTTTacc 
FOXO1 TGTTTac 
CP2 ttgTCTGGgt 
Sox18 gcCTTTG 
LEF-1 cCTTTGa 
LEF-1 cCTTTGa 
TCF-3 CTTTGa 
LEF-1 CTTTGa 
BRN1 aAATGCa 
PPARgamma:RXR-alpha catggttAAAGGcaa 
Smad3 caattcCAGACaggaag 
CP2 ttCCAGAcag 
Ets1 cagacAGGAAgaaag 
Smad2 AGACAg 
nerf agaCAGGAagaaaggcag 
SAP-1a acaGGAAG 
ER71 aCAGGAag 
Elk-1 cAGGAAg 
c-Ets-2 caGGAAG 
ELF1 AGGAAg 
SPI1 AGGAAg 
Spi-B gAAGAA 
PARP aAGAAA 
PPARgamma:RXRalpha, 
PPARgamma 
aagagggtagaaaTGACCtctga 
ER-alpha ggtagaaaTGACCtc 
ESRRA secondary motif agaaaTGACCtctgatt 
RXR-alpha aaTGACCtctg 
VDR:RXR-alpha aTGACCtc 
FXR TGACCt 
Xvent-1 gagCAAATggcac 
CTF1 atggcacaaTGCCA 
CTF1 TGGCAcaatgccac 
SOX10 cACAATg 
HES-1 aatgcCACGAggccc 
MAX secondary motif atgcCACGAggccc 
USF gCCACGaggc 
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HES-1 gcCACGAggc 
Kid3 CCACG 
Pbx gcccgatCTATC 
CDP CR1 ccgaTCTATc 
CDP CR3+HD ccgATCTAtc 
Helios A ctaTCCCTatg 
ATF1 secondary motif ctaTGACGgaatct 
CREB aTGACG 
CREB, ATF aTGACGgaa 
GATA-5 TATCTg 
p53 ctgctggcttggTCATGgct 
CP2/LBP-1c/LSF GCTGGcttggtcatg 
NFE2L2 ggcttgGTCAT 
Pasx-5 GTCATggct 
P73 gtcatggCTTGCtcctcagt 
GEN_INI cctCAGTT 
GEN_INI cctCAGTT 
GEN_INI cctCAGTT 
EGR1 secondary motif actctCCCACtctccc 
Tal-1 ccATCTG 
NMYC CATCTg 
ZF5 catctgCGCGCtc 
E2F-2 tctgCGCGCtcttat 
E2F-3 tctgCGCGCtcttat 
ZF5 tctgcgCGCTCtt 
ZF5 ctgCGCGC 
ZF5 ctGCGCGctctta 
GATA-5 gcgctcTTATCagtcct 
GATA-6 gcgctcTTATCagtcct 
GATA-1 gctctTATCAgtc 
GATA-1 tcTTATCagt 
GATA-4 tcTTATCagtc 
TR4 ACCCCtg 
Kaiso gccaggAGCAGg 
CTCF gagCAGGT 
CDP CR3 caggtattccTATCG 
GATA-2 ccttTTCCTc 
NFAT1 tTTTCC 
NF-AT4 tTTTCC 
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NF-AT1 tTTTCC 
Spi-B TTCCTc 
TFII-I CCTCCctcc 
GKLF CCTCCct 
GKLF CCTCCct 
Pax-4 cgcctcCACCCt 
Kid3 CCACC 
ZXDB CACCCtg 
ZXDA CACCCtg 
YB-1 tttagATTGG 
HOXA7 aGATTGg 
E2F-4 gATTGGgct 
c-Fos tggTGAGT 
STAT3 gctggcctccaGGAAAtctgg 
Thap1 gctggcctccaggaaatCTGGAgc 
STAT1 tccaGGAAA 
Elf5 ccaGGAAAtc 
Elf5 ccaGGAAAtc 
EHF ccaGGAAAtc 
Erg ccAGGAAa 
ESE-1 cAGGAAatc 
FEV caGGAAAt 
nerf attCAGGAagcaggggtc 
c-Ets-2 caGGAAG 
c-Ets-1 68 caGGAAGc 
Elk-1 cAGGAAg 
ELF1 AGGAAg 
SPI1 AGGAAg 
TR4 caGGGGT 
ZXDA aGGGGTc 
ZXDB aGGGGTc 
GKLF gCCCTCgcccacg 
EGR4 cctCGCCCacgctgcg 
EGR1 ctCGCCCacgctgc 
Egr-1 tcgCCCACgctg 
NGFI-C tcgCCCACgctg 
Egr-2 tcgCCCACgctg 
EGR-1 tcgCCCACgct 
Egr-3 tcgcCCACGctg 
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ZIC3 secondary motif gcccaCGCTGcgcca 
Egr-1 gCCCACgct 
Kid3 CCACG 
NR3C1 ccaGCACTtgtttctcca 
SRY TTGTTt 
FOXO1A tTGTTT 
Spi-B TTCTCc 
Rb:E2F-1:DP-1 gtTAGCGc 
E2F-2 ttagCGCGCggtgag 
ZF5 taGCGCGcggtga 
ZF5 tagCGCGC 
ZF5 GCGCGcgg 
Sp1 cggtgaGGGGAggggag 
BCL6B secondary motif ggtgagGGGAGgggag 
GKLF gaggGGAGGggaga 
ETF gaggGGAGGgg 
MAZ gGGGAGgg 
CKROX gggGAGGGg 
Spi-B gGAGAA 
Tal-1 (Scl) ggaGAAAAggaaa 
GATA-2 aAGGAAaggg 
GKLF aaggGGAGGggagg 
ETF aaggGGAGGgg 
MAZ aggGGAGGggaggg 
Sp1 aggggaGGGGAgggaaa 
MAZ gGGGAGgg 
CKROX gggGAGGGg 
BCL6B secondary motif ggggagGGGAGggaaa 
ETF gaggGGAGGga 
MAZ gGGGAGgg 
NFAT1 GGAAAa 
NF-AT4 GGAAAa 
NF-AT1 GGAAAa 
TFII-I aAGGAGgtgg 
GKLF aaGGAGG 
Pax-4 aGGTGGgaagg 
Kid3 GGTGG 
TF3C-beta caaggaggccggcccGGTGGgg 
GKLF aaGGAGG 
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Zic1 ggcccggtGGGGGc 
TAFII250 gcCCGGT 
ctcf cccggtgggGGCGGga 
KROX ccggtGGGGGcggg 
Sp4 ccggtggGGGCGggacc 
Sp2 cggtgggGGCGGgac 
BCL6B secondary motif cggtggGGGCGggacc 
Kid3 GGTGG 
SP1:SP3 ggtGGGGGcgg 
EGR1 ggtGGGGGcgggac 
WT1 ggtggGGGCG 
WT1 gtggGGGCGgga 
Egr-1 gtGGGGGcgg 
CPBP gtGGGGG 
Egr gtGGGGGcggg 
Sp1 tgggGGCGGgacc 
GC box tgggGGCGGgaccc 
ETF tgggGGCGGga 
ZF5 GGGGGcgg 
Sp1 ggGGCGGgac 
E2F1 gggGCGGGacc 
SP2 gGGCGGgac 
TAFII250 ACCCGac 
BRN1 tGCATTt 
Pax-4 gctctCCACCt 
Kid3 CCACC 
Ikaros ccTCCCA 
BEN CAGCGccc 
ZF5 cagCGCCC 
LRF agcgCCCCC 
WT1 CGCCCcctcc 
CPBP CCCCCtc 
IRF4 secondary motif ccctcCGAGAtcccg 
SMAD4 cccggggAGCCAgct 
ZIC3 secondary motif cagctTGCTGggaga 
Pax-5 cagcttgctgggaGAGCGggacggtccg 
Pax-3 tgggagagCGGGAcggtccgg 
E2F1 agaGCGGGacg 
TCFAP2C secondary motif aagcccagAGGCAg 
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TFAP2C AGCCCagaggca 
TFAP2A aGCCCAgaggcagag 
TFAP2B agcccagAGGCA 
TFAP2C agcccagAGGCA 
IRF3 secondary motif ggaaAAAGGgccga 
NF-AT1 GGAAAa 
NF-AT4 GGAAAa 
NFAT1 GGAAAa 
Foxn4 ccgaaggGACGCaccacgccag 
AhR:Arnt gacgcacCACGCcagcccc 
AhR cacCACGCcagccccagc 
Kid3 CCACG 
CPBP GCCCCag 
BEN CAGCGaca 
BEN CAGCGaca 
FOXN4 secondary motif cgacagccaaCGCCTcttgcag 
NF-1C caGCCAA 
ZF5 caGCGCGgcggct 
ETF gcGGCGG 
REST cttcgaaGCCGCcgccc 
ETF CCGCCgc 
AP-4 ccgcccggAGCTGccctt 
PPARgamma:RXR-alpha tgcCCTTTcctcttc 
GATA-2 ccctTTCCTc 
Spi-B TTCCTc 
TAFII250 ctTCGGT 
Spic ggaGGAAGca 
Spi-B gAGGAA 
ELF1 AGGAAg 
SPI1 AGGAAg 
LTF gaaAGTGCc 
GEN_INI GACTGacg 
GEN_INI GACTGacg 
GEN_INI GACTGacg 
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